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It is almost precisely 100 years ago that Auguste D. reported to a 
German psychiatrist in Frankfurt with the words: ‘I lost myself’. 
The psychiatrist was none other than Alois Alzheimer, and this day 
should mark the beginning of Alzheimer’s disease research. 
Christian Haass, 2004 
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Summary 9
SUMMARY 
Accumulation of the β-amyloid peptide (Aβ) in the central nervous system (CNS) is an 
invariant feature of the pathophysiology of Alzheimer’s disease (AD), the most common form 
of dementia in the elderly. The amyloidogenesis occurring in AD represents a fundamental 
membrane-related pathology involving a transmembrane substrate, the amyloid precursor 
protein (APP), that is metabolized by integral membrane proteases, the β-secretase (BACE) 
cleaving at the N-terminus, and the γ-secretase complex cleaving within the transmembrane 
domain at the C-terminus of the Aβ peptide (Selkoe, 2001). The alternative pathway involves 
the α-secretase that cleaves APP within the Aβ sequence and therefore prevents Aβ formation. 
Since α- and β-cleavages directly compete for their substrate APP, the key in understanding 
Aβ generation is to find out how access of these enzymes to APP is regulated. 
There is growing evidence that cholesterol plays an important role in AD pathology and 
particularly in the regulation of Aβ production. Cholesterol determines and modulates the 
structural characteristics of membranes and is an important constituent of lipid rafts, dynamic 
entities enriched in sphingolipids, which can only be detected in living cells. Their in vitro 
counterparts are detergent resistant membrane domains (DRMs), which can be isolated by 
cellular fractionation procedures. DRMs were shown to be critically involved in the regulation 
of APP processing, and it was demonstrated that changes in cholesterol levels exert their 
effects by altering the distribution of APP-cleaving enzymes within the membrane.  
Given the fundamental role of cholesterol in membrane organization and function we studied 
the consequences of cholesterol depletion on DRM formation, APP processing and Aβ 
generation in the murine brain. Mice with a targeted disruption in the dhcr24 gene (DHCR24-
/- mice) are entirely devoid of cholesterol, while heterozygous mice (DHCR24+/-) depleted of 
only one dhcr24 allele show moderately reduced brain cholesterol levels by about 25%. These 
two mouse models allow the analyses of cholesterol concentration-dependent changes in 
DRM composition and their functional consequences in vivo.  
Here we show that cholesterol depletion in a dose-dependent manner resulted in disorganized 
DRMs in brains of DHCR24+/- and DHCR24-/- mice. This was associated with inefficient 
plasminogen binding and plasmin activation and the displacement of β-secretase (BACE) 
from DRMs to APP-containing membrane fractions. In DHCR24+/- mice the moderate 
cholesterol depletion resulted in increased β-cleavage of APP and high levels of Aβ peptides. 
In contrast, DHCR24-/- mice exhibited a clear shift towards the non-amyloidogenic pathway, 
with reduced β-cleavage and diminished Aβ formation. These results show that membrane 
cholesterol regulates APP processing by altering the subcellular distribution of involved 
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proteins, but they clearly demonstrate that the steady state of Aβ is not maintained in 
membranes completely devoid of cholesterol, possibly due to reduced proteolytic activity of 
involved secretases.  
DHCR24-/- mice gradually accumulate the direct precursor of cholesterol, desmosterol, that 
was shown to account for 99% of all sterols in these mice. In adult knock-out mice the 
concentration of desmosterol was comparable to that of cholesterol in aged-matched wildtype 
mice. In contrast to young DHCR24-/- mice, age-related desmosterol accumulation and 
integration in membranes of adult DHCR24-/- mice resulted in formation of functional 
membranes, DRM formation and sustained APP metabolism. These observations suggest that 
desmosterol is capable of substituting cholesterol in biological membranes, insofar it is 
abundant enough, ensuring proper DRM formation and physiological APP processing in vivo. 
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ZUSAMMENFASSUNG 
Die Alzheimer Krankheit ist die häufigste Form der Altersdemenz und betrifft bis zu 10% der 
über 65-jährigen. Obgleich die Ursache und der zugrunde liegende Mechanismus der 
Krankheit noch immer nicht genau bekannt sind, scheint die Anhäufung und krankhafte 
Ablagerung von Amyloid-β-Peptiden (Aβ) im Gehirn von Alzheimer-Patienten ein wichtiger 
Auslöser für den massiven Verlust von Nervenzellen zu sein. Daher ist die Entstehung von Aβ 
für die Forschung von besonderem Interesse. Das Amyloid-Vorläuferprotein APP ist ein 
Membranprotein und wird von unterschiedlichen Enzymen geschnitten, wobei es bei der so 
genannten amyloiden Prozessierung zur Entstehung von Aβ kommt, bei der harmlosen nicht-
amyloiden Prozessierung allerdings kein Aβ gebildet wird. Diese Tatsache macht sich die 
Wissenschaft zunutze, indem sie Faktoren erforscht, welche den harmlosen 
Prozessierungsweg ankurbeln.  
Cholesterin ist ein wichtiger Bestandteil zellulärer Membranen und es wurde gezeigt, dass die 
Veränderung des Cholesteringehaltes in einer Zelle sich auf die Bildung von Aβ auswirkt. Da 
es allerdings keine effiziente Möglichkeit gibt, Cholesterin aus dem Gehirn von Versuchtieren 
zu entfernen, konnte man bislang nicht untersuchen, wie sich ein veränderter 
Cholesteringehalt auf die Aβ Bildung im lebenden Organismus auswirkt.  
In der vorliegenden Arbeit wurde ein Mausmodell untersucht, dem im homozygoten Fall 
beide Allele des dhcr24 genes fehlen, welches für ein Protein kodiert, das eine zentrale Rolle 
in der Cholesterinbiosynthese spielt. Diese DHCR24-/- Mäuse sind nicht in der Lage 
Cholesterin herzustellen, akkumulieren allerdings im Alter ein Vorläufer des Cholesterins, das 
Desmosterin. Wir konnten zeigen, dass heterozygote DHCR24 Mäuse (DHCR24+/-), denen 
nur ein dhcr24 Allel fehlt, bis zu 25% weniger Cholesterin aufweisen, was ein gutes Modell 
für eine partielle Cholesterin Verminderung darstellt. In beiden Genotypen wurden massive 
Veränderungen der Membranbeschaffenheit nachgewiesen, die ganz klar mit dem 
Cholesteringehalt korrelierten. Die Untersuchungen dieser Veränderungen auf die Bildung 
von Aβ haben gezeigt, dass im Falle der partiellen Cholesterin Verminderung eine deutliche 
Erhöhung von Aβ im Gehirn der heterozygoten Tiere zu verzeichnen war, wohingegen eine 
gänzliche Verarmung an Cholesterin zu einer Verminderung von Aβ führte. Diese Ergebnisse 
lassen sich am besten dadurch erklären, dass durch die Cholesterin Verminderung die relative 
Verteilung von APP und den es schneidenden Enzymen innerhalb der Membran derart 
verändert ist, dass es zu einer Erhöhung der Schnittfrequenz zwischen Substrat und Enzymen 
kommt. Ist die Membranbeschaffenheit durch vollständige Cholesterin Verarmung jedoch so 
sehr gestört, dass Aktivität und Funktion von ansässigen Membranproteinen geschmälert sind, 
Zusammenfassung 12 
bleibt die amyloide Prozessierung von APP weitgehend aus, wie im Gehirn von jungen 
DHCR24-/- Tiere nachgewiesen werden konnte. Weiterhin wurde untersucht, ob Desmosterin, 
welches in erwachsenen DHCR24-/- Mäusen in genauso grossen Mengen vorhanden ist wie 
Cholesterin in den Kontrollmäusen, die Rolle von Cholesterin übernehmen kann. 
Membrananalysen und Funktionsuntersuchungen haben ergeben, dass Desmosterin ein guter 
Ersatz für Cholesterin ist, und dass die in den jungen DHCR24-/- Mäusen detektierten 
Veränderungen durch die Akkumulation und Integration von Desmosterin in die 
Zellmembranen erwachsener Mäuse rückgängig gemacht werden konnten. 
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1. INTRODUCTION 
 
1.1 ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is a devastating neurodegenerative disease and the most common 
cause of dementia today. It is estimated that more than 10% of people over the age of 65 are 
affected and, with this sector of the population increasing more rapidly than any other, it is 
easy to see why determining the cause of the disease with a view to developing therapies is 
the focus of much current research.  
One of the first clinically recognized symptoms of AD is diminished performance on tests 
assessing declarative memory function. Apathy defined by loss of drive, motivation or lack of 
feeling or emotion is the most common neuropsychiatric symptom in AD, and increases with 
disease progression. The destructive neurodegenerative disorder slowly corrodes the brain 
until memories, moods and many other cognitive traits are permanently lost (Mega et al., 
1996). On external examination the brains of AD patients often show some degree of atrophy 
(Figure 1A) and dilatation of the lateral ventricles due to loss of brain tissue (Fox et al., 1996; 
Juottonen et al., 1998). The two most prominent neuropathological hallmarks of AD are 
extracellular deposition of the amyloid β-peptide (Aβ) in senile plaques (SPs) and the 
appearance of intracellular neurofibrillary tangles (NFTs) (Figure 1B). SPs are spherical 
lesions in the cerebral cortex, measuring up to 100 microns. In their fully developed stage - 
the neuritic plaque - SPs have a central core of Aβ in a fibrillary fine structure surrounded by 
dystrophic neuronal processes with neurofibrillary degeneration.  
 
 
Figure 1 Brain atrophy due to neurodegeneration (A) and the concomitance of senile plaques, consisting of β-
amyloid, and neurofibrillary tangels, consisting of hyperphosphorylated tau (B) are major neuropathological 
hallmarks of AD.  
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The zone around the amyloid core also contains reactive astrocytes and microglia. In addition 
to neuritic plaques, Aβ is also found in diffuse, non-fibrillar deposits (diffuse plaques). 
Diffuse plaques do not disrupt the neuropil. They are sometimes seen in large numbers in old, 
non-demented people and are not associated with dementia (Ogeng'o et al., 1996).  
NFTs are deposits of hyperphosphorylated tau filaments in the neuronal body. Similar 
deposits are present in the dystrophic processes that surround the amyloid core of SPs and in 
dendrites (neuropil threads). In severe AD, the hippocampus often contains extracellular NFTs 
embedded in the neuropil, like fossilized skeletons of neurons. The mechanism of 
accumulation of tau in NFTs is unclear.  
 
1.1.1 The Disease Hypotheses  
AD is regarded as an age-related but not an age-dependent disease (Braak and Braak, 1995). 
Several hypotheses have been proposed in order to explain this age-relationship, including 
systemic metabolic changes (Mattson et al., 1999), altered calcium homeostasis (Begley et al., 
1999), neurotransmitter dependency (Religa and Winblad, 2003), and neuronal oxidative 
stress (Mattson et al., 1999). However, none of these have provided a conclusive explanation 
for the molecular hallmarks of the disease, which combined result in selective neuronal loss. 
Given the molecular pathology of AD, two major hypotheses have been proposed: the 
‘amyloid cascade’ hypothesis (Hardy and Higgins, 1992) and the ‘neuronal cytoskeletal 
degeneration’ hypothesis (Braak and Braak, 1995; Terry, 1998). The ‘amyloid cascade’ 
hypothesis basically states that the neurodegenerative process observed in AD brains is best 
explained as a series of events triggered by the abnormal processing of the amyloid-β 
precursor protein (APP), the consequences of which are the production, aggregation, 
deposition and toxicity of its Aβ derivative. On the other hand, since the observation that 
neurofibrillary changes may precede the deposition of amyloid plaques (Arriagada et al., 
1992a; Arriagada et al., 1992b), the staging hypothesis proposed by Braak and Braak accounts 
for the view that cytoskeletal changes are the main events leading to neuronal degeneration in 
AD brains. Although until recently both lines of research were somehow in dispute, the two 
hypotheses were reconciled to some extent by showing that an age-dependent process is 
required in order to render the brain vulnerable to Aβ-dependent toxicity (Geula et al., 1998). 
Even though toxic effects of Aβ on cells have been demonstrated in vitro and in vivo, the 
mechanism leading to Aβ-induced neuronal damage, as well as the true nature of the 
neurotoxic Aβ species, have not yet been resolved. Moreover, recent studies suggest that Aβ 
may not be toxic when deposited in amyloid plaques; instead its neurotoxic properties might 
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be attributed to the prefibrillar Aβ aggregates (McLean et al., 1999). This notion was 
supported by the observation that synaptic dysfunction could be observed even before the 
formation of amyloid plaques in transgenic animals (Terry et al., 1991). A revision of the 
amyloid cascade hypothesis is required in the light of increasing evidence that neurons secrete 
small, readily diffusible Aβ oligomers that are highly neurotoxic (Lambert et al., 1998). 
Moreover, insoluble pools of intracellular Aβ accumulate with time in neurons and may cause 
the onset of early AD-related cognitive deficits (Skovronsky et al., 1998). Given the important 
role of non-fibrillar Aβ aggregates in the pathogenesis of AD, the development of strategies to 
prevent their formation is of great importance. 
 
1.1.2 APP processing 
APP is part of a larger gene family that includes APP-like proteins (APLPs) 1 and 2. This 
family of proteins has a membrane-associated receptor-like structure composed of a large 
extracellular, a single transmembrane, and a short cytoplasmic domain. APP homologs are 
also found in Caenorhabditis elegans (Apl-1) (Daigle and Li, 1993) and Drosophila (APPL) 
(Martin-Morris and White, 1990). In mammals, APP is ubiquitously expressed as different 
isoforms in neuronal and non-neuronal tissues.  
Processing of APP, including Aβ production, represents a fundamental membrane-related 
pathology involving a membrane-bound substrate metabolized by integral membrane 
proteases (secretases) (Figure 2). Aβ is cleaved out of APP sequentially by β- and γ-secretase. 
The β-site APP cleavage enzyme BACE1 has recently been identified as a novel membrane-
bound aspartyl-protease (De Strooper and Annaert, 2000; Esler and Wolfe, 2001) and cleaves 
APP in its luminal domain to generate a secreted ectodomain (sAPPβ). The remaining 10 kD 
β-cleaved C-terminal fragment of APP (β-CTF) fragment is subsequently the substrate for γ-
secretase complex cleaving within the transmembrane domain at the C-terminus of the Aβ 
peptide (Selkoe, 2001), which leads to the release of Aβ (amyloidogenic pathway). The γ-
secretase is a protein complex composed of presenilin (PS), nicastrin (NCT), APH-1 and 
PEN-2. PS 1 and PS 2 are required for intramembrane cleavage of an increasing number of 
type I membrane proteins, including the Notch receptor, which signals during differentiation 
and development. While PS1 and PS2 function as catalytic subunit, all four proteins are 
necessary for proteolytic activity of the complex (De Strooper, 2003). γ-secretase cleavage 
can take place at position 40 as well as position 42 of Aβ. Under physiological conditions, 
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Aβ40 levels are approximately 10 fold higher than those of Aβ42, while the latter is more prone 
to aggregate (Davis-Salinas and Van Nostrand, 1995).  
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Figure 2 APP processing and Aβ generation. Aβ is derived by sequential proteolytic cleavage of APP. The non-
amyloidogenic pathway is initiated by α-secretase cleavage of APP within the Aβ sequence thus precluding Aβ 
formation, generating a secreted ectodomain (sAPPα) and a shorter α-cleaved C-terminal fragment of APP (α-
CTF) that is subsequently cleaved within the transmembrane domain by the γ-secretase complex producing the 
small P3 peptide. Amyloidogenic APP processing involves the β-secretase cleavage at the N-terminus, and the γ-
secretase complex at the C-terminus. β-secretase cleavage releases a secreted ectodomain (sAPPβ) and generates 
a C-terminal fragment of APP (β-CTF), which is subsequently cleaved by the γ-secretase leading to the secretion 
of Aβ. 
 
The alternative pathway (non-amyloidogenic pathway) involves the α-secretase, a member of 
the ADAM family of disintegrin and metalloproteases (ADAM 9, 10, and 17) (Buxbaum et 
al., 1998; Koike et al., 1999; Lammich et al., 1999) that cleaves APP within the Aβ sequence 
to generate a secreted ectodomain (sAPPα), a shorter α-cleaved C-terminal fragment of APP 
(α-CTF) that is also cleaved by the γ-secretase to release a short fragment (P3) - the C-
terminal part of Aβ. In addition, the γ-secretase cleavage of α- and β-CTFs produces the APP 
intracellular domain (AICD). α-cleavage is the dominant processing step under physiological 
conditions, and since it cuts APP within the Aβ region it prevents Aβ formation.  
Despite numerous studies, the physiological function of APP and its cleavage products remain 
unclear. Some evidence implies the soluble ectodomain and AICD in signaling and in a series 
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of physiological responses (Kimberly et al., 2001; Mattson et al., 1997). While it is possible 
that one does not need to understand these functions to understand the role of Aβ in AD, it is 
certainly not excluded that disturbance of normal APP function contributes to the disease 
process as well (Stokin et al., 2005). Moreover, after more than 15 years of intense research, 
understanding the biology of APP remains an important scientific and intellectual challenge. 
 
1.1.3 Familial Alzheimer’s disease (FAD) 
From the genetical point of view, AD is a complex, heterogeneous disease that follows an 
age-dependent dichotomous model (Tanzi, 1999). On one hand, the early-onset familial form 
of AD (EOFAD) is caused by defects in any of three different genes: PS1 on chromosome 14 
(Sherrington et al., 1995), PS2 on chromosome 1 (Levy-Lahad et al., 1995), and APP on 
chromosome 21 (Goate et al., 1991). On the other hand, late-onset AD (LOAD) is associated 
with genetic polymorphisms that appear to operate as risk factors and/or genetic modifiers. 
While the mutations in APP and the presenilins account for less than 5% of all AD cases, they 
are fully penetrant and therefore guarantee onset of the disease. Disease causing mutations in 
the APP gene are clustered around the α-, β- and particularly the γ-secretase cleavage sites, 
resulting in, for example, preferred amyloidogenic processing of APP (Hsiao et al., 1995) and 
an increased ratio of Aβ42 to Aβ40, thus in favor of the more hydrophobic form of Aβ (Walker 
et al., 2005). By far the highest number of mutations has so far been identified in the PS 
genes. These mutations appear to act as gain of function mutations leading to higher levels of 
Aβ42 in plasma of affected patients, as well as in media of cultured fibroblasts from these 
patients (Scheuner et al., 1996). 
 
1.1.4 Genetic and non-genetic risk factors for AD  
The first and until now the only consistently replicated genetic risk factor for LOAD is the ε4 
variant of the gene encoding the Apolipoprotein E (ApoE). The glycoprotein ApoE is the 
major component of very low-density lipoproteins (VLDL) and the predominant 
apolipoprotein in the central nervous system (Corder et al., 1993; Puglielli et al., 2003). ApoE 
is the principal cholesterol protein carrier in the brain and critical for the coordination of 
cholesterol in the repair, growth, and maintenance of myelin and neuronal membranes during 
development or after injury (Boyles et al., 1990; Goodrum, 1991; Ignatius et al., 1986). The 
apoe gene exists in three isoforms: ε2, ε3, and ε4. In the normal population, the ε3 allele is the 
most common followed by the ε4 allele (Strittmatter and Roses, 1995). Inheritance of the ε4 
allele has been shown to be associated with a reduced regional cerebral blood flow in several 
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brain regions in non-demented carriers (Reiman et al., 2001) and several studies have shown 
that its inheritance is associated with elevated cholesterol levels and increased risk of 
developing AD compared to individuals with only the apoe ε2 or ε3 alleles (Corder et al., 
1993; Hofman et al., 1997; Strittmatter et al., 1993). The ε4 allele has also been associated 
with familial hypercholesterolemia (Eto et al., 1988).  
The mechanism behind the contribution of ApoE to an increased risk of AD is currently under 
intense investigation. apoe knock-out mice show a reduced deposition of Aβ (Bales et al., 
1997). Furthermore, the isoform of ApoE that is derived from apoe ε4 expression binds with 
high affinicy to Aβ peptides (Beffert et al., 1998) and its expression increases the formation of 
Aβ fibrils, an effect that seems to be isoform specific (Holtzman et al., 2000). Under normal 
non-pathological conditions, ApoE is associated with a lipid source and, by adding 
extracellular Aβ to neuronal cell cultures, this stimulates the ApoE-mediated internalization of 
cholesterol (Beffert et al., 1998). An alternative mechanism by which apoe ε4 increases the 
risk of AD may however be more closely related to the intracellular homeostasis of 
cholesterol. Some findings suggest that the apoe ε4 allele is associated with a decreased 
cholesterol efflux compared with ε2 and ε3 alleles (Michikawa et al., 2000).  
It is increasingly recognized that vascular risk factors also play a role in Alzheimer’s type 
dementia. In the early 1990s, one found increased prevalence of senile plaques in patients 
with coronary artery disease, linking vascular conditions to AD neuropathology (Sparks et al., 
1990; Sparks et al., 1993). Since then multiple studies have supported the idea that vascular 
conditions such as hypertension, atherosclerosis and hypercholesterolemia increase the risk 
for AD (Sjogren and Blennow, 2005). Confirmation of the role of these vascular-related 
conditions in dementia would suggest possible changeable risk factors that may serve as 
targets for strategies of prevention. With the advance of cholesterol-lowering drugs such as 
statins, high cholesterol levels are potentially modifiable risk factors (see paragraph 1.2). 
 
1.1.5 Clearance of Aβ from the brain 
Despite the fact that Aβ is produced as a normal consequence of APP metabolism (Haass et 
al., 1992), Aβ fibrils do not accumulate in large quantities in healthy individuals. This 
indicates the existence of clearance mechanisms and suggests that Aβ deposition is the net 
result of a balance between its production and catabolism. Aβ clearance occurs by at least 
three pathways: extracellular proteolysis, transport across the blood–brain barrier (BBB), and 
receptor-mediated endocytosis. Two metalloproteinases, the insulin-degrading enzyme (Qiu et 
al., 1998) and the membrane-anchored zinc endopeptidase neprilysin (Carson and Turner, 
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2002), have been implicated in the extracellular degradation of Aβ. Infusion of neutral 
endopeptidase inhibitors in the rat brain resulted in abnormal deposition of endogenous Aβ 
(Iwata et al., 2000), highlighting the importance of extracellular degradative pathways in 
clearing Aβ. Another important protease involved in Aβ degradation is the serin protease 
plasmin (Selkoe, 2001). Plasmin activity is regulated by plasminogen-activators and inhibitors 
as well as plasminogen activator-inhibitors and plasmin inhibitors (Collen, 1999). In addition, 
plasmin generation is dependent on the binding of plasminogen to the plasma membrane 
(Plow et al., 1995). It was shown that brain tissue from AD patients contains reduced levels of 
plasmin, implying that plasmin down-regulation may cause amyloid plaque deposition 
accompanying sporadic AD (Ledesma et al., 2000). Aβ transport across the BBB is less well 
understood, but gp330/megalin and its ligand ApoJ may be involved. ApoJ, the predominant 
Aβ-binding protein in cerebrospinal fluid, mediates binding of Aβ to gp330 (Hammad et al., 
1997). Aβ can also be removed by binding to endocytic receptors, probably including the 
class A and class B scavenger receptors, which can bind to and internalize fibrillar forms of 
Aβ (Paresce et al., 1996). On the other hand, Aβ can form complexes with low-density 
lipoprotein-related receptor protein (LRP) ligands such as ApoE (Yang et al., 1999), which 
can then be internalized via LRP (Kang et al., 2000).  
 
1.1.6 Treatments and possible treatment strategies of AD 
The observation of a deficiency in cholinergic neurotransmission in AD led to the 
development of cholinesterase inhibitors as the first approved treatment for dementia 
symptoms. The cholinergic hypothesis states that decreased cholinergic transmission, due to 
depletion of cholinergic neurons, plays a major role in the expression of cognitive, functional, 
and possibly behavioral symptoms in AD (Bartus et al., 1982). The mechanism of action of 
cholinesterase inhibitors is to increase the availability of acetylcholine through an inhibition 
of the catabolic enzyme acetylcholinesterase. Another approach to the treatment of AD is to 
block glutamatergic neurotransmission. Glutamate is the main excitatory neurotransmitter in 
the brain. One of its receptors, N-methyl D-aspartate (NMDA), has been implicated in long-
term potentiation, which is the neuronal mechanism responsible for learning and memory 
(Katsuki et al., 1997; Rondi-Reig et al., 2001). Too much stimulation, however, leads to 
excitotoxicity due to high intracellular concentrations of calcium, which causes neuronal 
dysfunction and death (Michaelis, 1998), effects involved in the pathogenic cascade of AD. 
Memantine, a non-competitive NMDA antagonist, blocks glutamate-mediated excitotoxicity 
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but leaves the physiological activation of the NMDA receptor during neurotransmission 
unchanged (Molinuevo et al., 2004).  
Retrospective observational studies have shown that the use of two groups of widely 
prescribed substances may have a protective effect against the development of AD (Etminan 
et al., 2003; in t' Veld et al., 2001). One group combines the non-steroidal anti-inflammatory 
drugs (NSAIDs). In a meta-analysis of nine studies, the use of NSAIDs was associated with a 
lower risk of developing AD, and the benefit was greater with long-term use than with 
intermediate use (Etminan et al., 2003). Whether the protective effects of NSAIDs will hold 
up in prospective studies is an open question. The other group represents the cholesterol-
lowering drugs, so called statins (see chapter 1.2). 
The basis for an interesting new therapeutic approach was laid by Dale Schenk and colleagues 
in 1999, who actively immunized transgenic APP mice with Aβ42. They reported that 
immunization of young animals essentially prevented the development of β-amyloid-plaque 
formation, neuritic dystrophy and astrogliosis, and treatment of the older animals also 
markedly reduced the extent and progression of these AD-like neuropathologies. These results 
raised the possibility that immunization with amyloid-β may be effective in preventing and 
treating AD (Schenk et al., 1999). Other studies have reproduced these results using different 
models (Morgan et al., 2000), and passive immunization with antibodies against human Aβ 
also decreased Aβ in transgenic mice and improved performance in test behaviors (DeMattos 
et al., 2001). Based on these preclinical findings, a multicenter randomized double-blind 
placebo-controlled Phase II trial was organized to test the safety and efficacy of active Aβ42 
immunization in humans, which has to be halted due to adverse effects (Gilman et al., 2005; 
Orgogozo et al., 2003). Despite this early halt of the trial, follow-up examinations of some of 
the patients revealed the presence of antibodies recognizing amyloid plaques in the immune 
sera of the patients (Hock et al., 2002), as well as a stabilization of the cognitive decline in 
immunized patients (Hock et al., 2003). Moreover, neuropathological evaluation of two 
immunized cases showed areas with unusually reduced amyloid burden and evidence of Aβ-
associated microglia, suggesting that the immunization had increased Aβ clearance by 
activated microglia (Ferrer et al., 2004; Nicoll et al., 2003). Based on these observations, new 
vaccines are being developed at present and remain highly promising strategies for further 
testing and possible entry into clinical practice. 
Since Aβ peptides are produced by sequential processing of APP by the two aspartyl-type 
proteases β- and γ-secretase, these secretases are a center of attraction for various drug 
discovery efforts. Although a large number of specific drug-like γ-secretase inhibitors have 
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been discovered, progress towards the clinic has been slowed by the broad substrate 
specificity of this unusual intramembrane-cleaving enzyme (Steiner and Haass, 2000). In 
particular, the Notch receptor depends on γ-secretase for its signaling function and, thus, γ-
secretase inhibition produces distinct phenotypes related to a disturbance of this pathway in 
preclinical animal models. The main task now is to define the therapeutic window in human 
between desired central efficacy and Notch-related side effects (Beher and Shearman, 2002). 
In contrast, most studies with knock-out animals have indicated that β-secretase inhibition 
may have minimal adverse effects (Dominguez et al., 2001). However, the properties of the 
active site of this enzyme make it difficult to find small-molecule inhibitors that bind with 
high affinity (Beher and Graham, 2005). 
 
 
1.2 CHOLESTEROL AND AD 
Over the past decade, an increasing amount of evidence derived from genetic, epidemiological 
and biochemical studies has pointed to a role for cholesterol in the development of AD, and 
particularly in the regulation of APP processing. As mentioned above, the major risk factor, 
after age, is the presence of the apoe ε4 allele, and also other genes related to cholesterol 
metabolism have been linked to AD, although none as unequivocally as apoe. These include 
the gene encoding LRP (Kang et al., 2000) and cyp46, which encodes cholesterol 24-
hydroxylase, the enzyme responsible for the catabolism of cholesterol to 24S-
hydroxycholesterol (24S-OH-chol) (Lutjohann et al., 2000). Epidemiological studies reported 
that levels of total cholesterol and low-density lipoprotein (LDL) in serum were shown to 
correlate with the amount of Aβ in AD brains (Kuo et al., 1998), and there is epidemiological 
evidence that elevated cholesterol levels during mid-life increase the risk of developing AD 
(Kivipelto et al., 2001) (see also 1.1.4). Several retrospective studies have suggested that the 
use of statins is associated with a reduced prevalence of AD (Jick et al., 2000; Rockwood et 
al., 2002; Wolozin et al., 2000; Yaffe et al., 2002). Statins are a highly successful class of 
cholesterol lowering drugs inhibiting the Hydroxy-3-methylglutaryl coenzyme A reductase 
(HMGCR), a rate limiting enzyme in the isoprenoid and cholesterol biosynthesis (see 1.2.1), 
and thereby decrease LDL and increase high-density lipoprotein (HDL) levels (Jula et al., 
2002). Clinical trials with statins in AD patients, however, revealed controversial data. 
Alterations in APP cleavage products such as sAPPα, sAPPβ and Aβ were detected in the 
cerebrospinal fluid of treated AD patients (Simons et al., 2002; Sjogren et al., 2003), while 
only in one study a prevented decline of cognition in AD patients was reported (Masse et al., 
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2005). Several mechanisms have been suggested for the decreasing risk of AD by statin use, 
one of the most prevailing being that statins affect the metabolism of Aβ (see chapter 1.2.3). 
The causal theory of pharmacologic benefit from statins reiterates the lipid hypothesis, which 
states that dyslipidemia is central to the process of atherosclerosis and the clinical benefit 
which accrues from statin therapy is a function of the degree of lipid lowering. The non-causal 
theory supports the premise that clinical benefits are related primarily to pleiotropic effects of 
statins (Farmer, 2000). These pleiotropic effects include endothelial protection through 
modulation of eNOS and NO production, antioxidant and anti-inflammatory effects. Statins 
also reduce the levels of isoprenoids, which are derived from intermediates of the cholesterol 
biosynthetic pathway. These intermediates, such as farnesyl- and geranylpyrophosphate, serve 
as important lipid-attachment molecules for the posttranslational modification of many 
proteins, including heterotrimeric G proteins and small GTP-binding proteins such as RAS 
and Rho. These molecules play fundamental roles both in cell growth and in signal 
transduction and mitogenic pathways (Coleman and Olson, 2002; Olson et al., 1995). 
Moreover, the production of Aβ was correlated with the levels of cholesterol esters (Puglielli 
et al., 2001; Puglielli et al., 2003), suggesting the involvement of Acyl-coenzyme 
A:cholesterol acyltransferase (ACAT), the enzyme that removes excess cholesterol from 
membranes and converts free cholesterol to cholesterol esters for storage purpose (Rudel et 
al., 2001). 
 
1.2.1 Metabolism of cholesterol  
Cholesterol is provided to the cell through endogenous synthesis or uptake. Cholesterol 
synthesis occurs only in the liver and the brain, through a multi-component pathway that 
begins with the condensation of acetoacetyl-CoA with acetyl-CoA to produce mevalonate in a 
set of reactions that are catalyzed by Hydroxy-3-methylglutaryl coenzyme A synthase 
(HMGCS) and HMGCR. The first intermediate committed to the production of sterols is C30 
squalene, which is converted to lanosterol. Cholesterol biosynthesis proceeds via two 
intersecting routes involving the same enzymes, the Kandutsch-Russell-pathway with 7-
dehydrocholesterol as the direct precursor, and the Bloch synthesis pathway with desmosterol 
as the ultimate precursor of cholesterol (Figure 3) (Waterham et al., 2001). DHCR24, the 3β-
hydroxysterol-∆24 reductase, is crucial for cholesterol biosynthesis, as it is the mediating 
enzyme between the two pathways – reducing the C24 double bond of the Bloch-pathway 
precursors – finally leading to the production of cholesterol. 
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After being produced, cholesterol is secreted by a group of transport molecules, such as the 
ATP-binding cassette transporter A1 (ABCA1), where it binds apolipoproteins to form lipid-
protein complexes. HDL complexes accept cholesterol (and other lipids) to form LDL  
complexes, which are transported throughout the body. 
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Figure 3  Cholesterol biosynthesis can proceed from lanosterol via two intersecting routes, the Bloch- or the 
Kandutsch-Russell-pathway. The choice of pathway is determined by the stage at which the double bond at 
position C24 in the sterol side chain is reduced. If this double bond is retained until the last reaction, cholesterol 
synthesis proceeds via desmosterol (Bloch-pathway), whereas early reduction leads to the formation of 
lathosterol and 7-dehydrocholesterol (Kandutsch-Russell-pathway). DHCR24 is the mediating enzyme between 
the two pathways. 
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1.2.2 Brain cholesterol 
Cholesterol metabolism in the brain parallels that in the periphery, but also differs in several 
important aspects. In the brain, the BBB effectively prevents cholesterol uptake from the 
circulation, and de novo synthesis is responsible for practically all cholesterol present in this 
organ. Cholesterol is synthezised by neurons, astroglia and oligodendrocytes, but in the adult 
the prevalent location of cholesterol synthesis appears to be in astrocytes. Once synthesized, 
astrocytes secrete cholesterol predominantly via the ABCA1 transporter, where it is taken up 
by particles that resemble HDL (Lee and Parks, 2005). Peripheral HDL differs from brain 
HDL in the content of apolipoproteins. Brain HDL contains mainly ApoE and ApoJ, while 
peripheral HDL contains large amounts of ApoA and small amounts of ApoE. After being 
generated, brain HDL is taken up by lipoprotein receptors of neurons. Many types of 
lipoprotein receptors are present in the brain, but one of the most abundant lipoprotein 
receptors in neurons is LRP (Zerbinatti and Bu, 2005). The life cycle of cholesterol in the 
neuron begins in the endoplasmic reticulum, where cholesterol is either taken up from 
endosomes or synthesized de novo. What follows is a cyclical mechanism where membrane in 
the endoplasmic reticulum is progressively enriched with cholesterol. 
Essentially all (about 99%) of brain cholesterol is unesterified. The majority of cholesterol 
present in the CNS is believed to reside in two different pools: one represented by the myelin 
sheaths (an estimated portion of 70%) and the other by the plasma membranes of astrocytes 
and neurons (Snipes and Suter, 1997). Cholesterol synthesis in the developing mammalian 
CNS is relatively high, but declines to a very low level in adults. This can be explained by an 
efficient recycling of brain cholesterol. Brain cholesterol has an extremely long half-life of 
about 5 years in humans (Bjorkhem et al., 1998), which makes it almost impossible to 
medicinally reduce brain cholesterol levels in adults. Although the cholesterol recycling 
system in the brain seems quite efficient, there are two known mechanisms for the excretion 
of cholesterol from the brain to maintain the steady state. The first is analogous to classic 
“reverse cholesterol transport” and is mediated by a flux of cholesterol present in ApoE 
containing lipoproteins through CSF into the circulation. The details of this particular 
mechanism for sterol transport are, however, not known (Ohyama et al., 2006). A 
quantitatively more important mechanism involves conversion of cholesterol to 24S-OH-
cholesterol, a more polar sterol that is able to traverse the BBB, enter the circulation and 
travel to the liver (Bjorkhem et al., 1998; Lutjohann et al., 1996). 24S-OH-cholesterol was 
also shown to be a regulator for the key enzymes in cholesterol biosynthesis, as well as a 
precursor for steroid hormones (Edwards and Ericsson, 1998).  
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All genes regulated by sterols contain a sterol-responsive element (SRE) within the 5’-
flanking region. Through the binding of SRE binding proteins (SREBPs), sterols are able to 
control the transcription of genes (Yokoyama et al., 1993).  
 
1.2.3 Cellular membranes and lipid rafts 
Plasma membranes consist of two leaflets that are asymmetric in lipid distribution, electrical 
charge, fluidity and function. Phosphatidylcholine and sphingomyelin (SPM) are concentrated 
in the brain exofacial leaflet of synaptic plasma membranes, while phosphatidylethanolamine, 
phosphatidylserine and phosphatidylinositol are enriched in the cytofacial leaflet. The large 
difference in fluidity between exo- and cytofacial leaflets is associated with the transbilayer 
distribution of cholesterol (Schroeder et al., 1988; Wood et al., 1989). While the exofacial 
leaflet is cholesterol-poor, it was shown that the cytofacial leaflet of plasma membranes from 
wildtype mice contains approximately 85% of the total amount of cholesterol (Igbavboa et al., 
1997; Igbavboa et al., 1996), organized in exchangeable and non-exchangeable cholesterol 
pools (Nemecz et al., 1988). Cholesterol determines and modulates the structural 
characteristics of membranes (Bloch, 1979; Bloch, 1983). According to the raft hypothesis, 
cellular membranes are not a homogenous mixture of lipids but contain entities enriched in 
sphingolipids and cholesterol, so called rafts, floating in the sea of glycerophospholipids 
(Simons and Ikonen, 1997). It is assumed that the presence of long and saturated acyl chains 
in sphingolipids should allow cholesterol to become tightly intercalated with such lipids, 
resulting in the organization of liquid ordered phases, whereas the unsaturated phospholipids 
are loosely packed and form a disordered state (Recktenwald and McConnell, 1981; Sankaram 
and Thompson, 1990). The difference in packing ability leads to phase separation. The 
hypothesis postulates that distinct proteins can selectively partition into lipid rafts, because 
many of them need to be in a cholesterol-rich environment to be active, indicating that rafts 
could serve as specific sites for molecular sorting and polarized transport. For example 
glycosyl-phosphatidylinositol (GPI) -anchored proteins tent to be constitutively associated 
with raft domains, while lipid modifications on these proteins allow them to intercalate into 
lipid raft structure (Simons and Ehehalt, 2002). Other proteins are less closely associated, and 
their movement in and out of rafts can be controlled by factors such as ligand-binding or 
oligomerization (Harder et al., 1998). Native rafts can only be detected in living cells (Simons 
and Toomre, 2000). The in vitro counterparts are detergent resistant membrane domains 
(DRMs), operationally defined as domains resistant to solubilization by non-ionic detergent at 
4°C (Brown and Rose, 1992), which can be isolated by cellular fractionation procedures. 
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However, caution needs to be exercised when equating DRMs with rafts in cell membranes 
(Lichtenberg et al., 2005). Lipid rafts are believed to play a central role in several cellular 
processes, most notably in membrane sorting and trafficking, and in signal transduction 
(Laude and Prior, 2004; Simons and Toomre, 2000). In these cases, rafts can act as platforms 
allowing particular proteins to cluster together to facilitate these processes.  
 
1.2.4 Cholesterols’ influence on APP processing 
There is growing evidence that cholesterol plays an important role in AD pathology and 
particularly in the regulation of APP processing. Studies examining the effects of cholesterol 
loading in cultured cells reported inconsistent consequences on APP processing and Aβ 
generation, while in vivo data demonstrate a strong link between high cholesterol levels and 
increased Aβ production (Refolo et al., 2000; Sparks et al., 1994). In contrast, treatment of 
guinea pigs with statins resulted in lower Aβ levels (Fassbender et al., 2001). Moreover, 
amyloidogenic processing of APP and brain Aβ load were significantly reduced in transgenic 
mice treated with BM15.766, a cholesterol-lowering drug, inhibiting DHCR7 (Refolo et al., 
2001). These results have been replicated in cultured cells by the use of statins and/or removal 
of existing cholesterol using methyl-β-cyclodextrin (Ehehalt et al., 2003; Kojro et al., 2001; 
Simons et al., 1998). 
Recent studies suggest that amyloidogenic processing of APP may be facilitated in lipid raft 
domains, and may therefore be dependent on cholesterol levels. DRMs were shown to 
contribute in the segregation of APP from BACE (Ehehalt et al., 2003). While endogenous 
APP and α-secretases were predominantly found in membrane compartments not associated 
with lipid rafts, BACE and the γ-secretase complex were shown to reside within rafts of late 
Golgi and early endosomes (Cordy et al., 2003; Riddell et al., 2001; Vetrivel et al., 2004). 
Hence, access of α- and β-secretase to APP, and therefore Aβ generation, may be determined 
by dynamic interactions of APP and its secretases with lipid rafts. A moderate reduction of 
cholesterol up to 30% was shown to result in disorganized DRMs, and led to increased β-
cleavage and higher Aβ production (Abad-Rodriguez et al., 2004). These data suggest that 
under physiological conditions lipids might build an invisible boundary, corralling the γ-
secretase complex and BACE away from their substrate, APP (Kaether and Haass, 2004). 
Thus, disruption of rafts through cholesterol depletion might lessen the sequestration of γ-
secretase and BACE into rafts and result in a higher proportion of these secretases in the APP 
containing fraction of the membrane, therefore cleaving APP more frequently, which would 
consequently lead to increased levels of β-CTF and Aβ (Abad-Rodriguez et al., 2004; Kaether 
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and Haass, 2004). However, depletion of cholesterol by a greater degree than 30% was shown 
to result in elevated levels of sAPPα, reduced β-cleavage and diminished Aβ production 
(Ehehalt et al., 2003; Kojro et al., 2001; Simons et al., 1998). This shift towards the non-
amyloidogenic processing seems to be a consequence of elementary cholesterol depletion-
changes in membrane organisation and secretase activity. Even though APP and its secretases 
are assumed to be in the same membrane compartment under these conditions, amyloidogenic 
processing is extensively prevented. There is some evidence that cholesterol depletion 
increases α-secretase activity, possibly due to the relocation of some ADAM10 from raft to 
non-raft fractions in vitro (Kojro et al., 2001). Moreover, it was shown that disrupting 
cholesterol transport can alter presenilin distribution within the cell and affect APP processing 
(Burns et al., 2003; Runz et al., 2002), and depletion of membrane cholesterol resulted in 
complete inhibition of γ-secretase cleavage (Wahrle et al., 2002). However, the majority of 
evidence indicates that alterations in β-secretase activity are largely responsible for the 
dependence of Aβ production on cholesterol levels. Cross linking experiments of APP and 
BACE in raft domains (Ehehalt et al., 2003) and targeting BACE exclusively to rafts (Cordy 
et al., 2003) have a remarkable effect on Aβ production that is cholesterol dependent. 
Furthermore, β-secretase activity in large unilamellar vesicles was shown to be directly 
influenced by membrane cholesterol concentrations (Kalvodova et al., 2005).  
 
1.2.5 Cholesterol biosynthesis and transport disorders 
Although the structure of cholesterol was elucidated by Wieland and Dane in 1932, the first 
genetic defect of the cholesterol biosynthetic pathway, mevalonic aciduria, due to deficiency 
of the enzyme mevalonate kinase, was identified in 1986. Since then, disorders of cholesterol 
biosynthesis have emerged as important errors of metabolism that collectively provided 
insight in many new genetic and biochemical aspects. Whereas most metabolic diseases are 
characterized by exclusively or largely postnatal biochemical toxicities or deficiencies, 
disorders of cholesterol biosynthesis are notable for their severe effects on prenatal 
development. The remarkable embryonic consequences of abnormal cholesterol biosynthesis 
are exemplified by the Smith-Lemli-Opitz syndrome (SLOS), a well-known multiple 
congenital anomaly syndrome only recently discovered to be caused by a deficiency in the 
DHCR7, the enzyme catalyzing the reduction of the ultimate precursor of cholesterol in the 
Kandutsch-Russel pathway (Opitz, 1999). SLOS patients reveal decreased plasma cholesterol 
levels and elevated concentrations of 7-dehydrocholesterol. Equally surprising has been the 
discovery that primary defects of cholesterol biosynthesis cause several different forms of 
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congenital skeletal dysplasia, most notably X-linked dominant chondrodysplasia punctata, or 
Conradi-Hunermann syndrome (Herman, 2003). Yet another sterol disorder, desmosterolosis, 
caused by defective activity of the 3β-hydroxysterol-∆24 reductase (DHCR24), combines a 
severe osteosclerotic skeletal dysplasia with multiple embryonic malformations similar to 
those of SLOS. Only two desmosterolosis patients are known to have survived beyond birth. 
These patients had elevated levels of the cholesterol precursor desmosterol in plasma and 
tissue, while cholesterol levels were relatively normal, depending on the mutations in the 
dhcr24 gene and their influence on the functional activity of DHCR24 (Andersson et al., 
2002; Fitzky et al., 2001; Waterham et al., 2001). In 2002, two unrelated males with 
lathosterolosis were described with different mutations in the Sterol C-5-desaturase gene 
(Brunetti-Pierri et al., 2002). Both patients exhibited an ‘SLOS-like’ phenotype and had 
abnormal sterol profiles with accumulation of lathosterol in plasma and cultured fibroblasts.  
The discovery of the biochemical basis of these diverse genetic disorders has provided 
accurate biochemical methods for their diagnosis and prenatal diagnosis, but the pathogenesis 
of these disorders is presently still unclear. One can postulate that pathogenicity results from a 
lack of cholesterol or related sterols, accumulation of toxic sterol intermediates above each 
enzyme block, abnormal feedback regulation of earlier steps in the pathway, including 
synthesis of key isoprenoid compounds, and/or abnormal signaling by hedgehog proteins that 
normally contain bound cholesterol. In 2003 it was shown that response to the hedgehog 
signal is compromised in mutant cells from mouse models of SLOS and lathosterolosis and in 
normal cells pharmacologically depleted of sterols (Cooper et al., 2003). The existence of 
naturally occurring or targeted mouse mutations for most of the disorders should facilitate 
mechanistic studies, particularly during development.  
 
1.2.6 DHCR24 knock-out mice  
C57BL/6x129SvEv mice with a targeted disruption in the dhcr24 gene were generated and 
published by Wechsler and colleagues in 2003, entitled “Generation of cholesterol-free mice”. 
Plasma and tissues of DHCR24-/- mice contained almost no cholesterol, and desmosterol was 
shown to account for 99% of total sterols (Wechsler et al., 2003). They reported that in a 
comprehensive patho-morphological analysis, DHCR24-/- mice at the age of three months 
revealed that all organs were normal in structure with the exception of testes, which were 
histological identical to degenerated testes seen in adult mice treated with a chemical inhibitor 
of DHCR24 (Singh and Chakravarty, 2003). The DHCR24-/- mice also had smaller stores of 
subcutaneous and mesenteric fat, and both males and females were infertile. This relatively 
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mild phenotype contrasts dramatically with the severe abnormalities observed in two 
registered patients with desmosterolosis who carry mutations in the dhcr24 gene (Andersson 
et al., 2002; FitzPatrick et al., 1998). This discrepancy may be due to the fact that maternal 
cholesterol is not available during human embryogenesis. In mice, cholesterol can pass the 
placenta and this addition of maternal cholesterol seems to take over the indispensable role of 
endogenously synthesized cholesterol in development. Since desmosterol is accumulating in 
these mice, the amount of total sterols in the periphery is unchanged and the nature of the 
accumulating sterol may explain why DHCR24-/- mice are viable, whereas mice deficient in 
other cholesterol biosynthetic enzymes are not viable embryonically (Fitzky et al., 2001; Herz 
and Farese, 1999). 
 
1.2.7 DHCR24/seladin-1 
DHCR24 shares homologies with a family of flavin-adenine-dinucleotide-dependent 
oxidoreductases and is the human homologue of the diminuto/dwarf1 gene, described in 
plants and in C.elegans (Klahre et al., 1998). In plants, Diminuto/Dwarf1 is required for the 
synthesis of brassinosteroids, which are plant sterols essential for normal growth and 
development. In 2000, Greeve et al. performed a differential display analysis and identified 
the mRNA of dhcr24 being down-regulated in brain areas affected by AD compared to non 
affected areas (Greeve et al., 2000). This is why they named it seladin-1, the selective 
Alzheimer’s disease indicator 1. The observed down-regulation suggested an association of 
seladin-1 with the selective vulnerability of neurons in these particular brain areas. Further 
experiments revealed a neuroprotective effect of seladin-1 over-expression in human SH-
SY5Y neuroblastoma cells (unpublished results by Crameri et al.) and neuroglioma H4 cells 
that were protected from apoptosis induced by oxidative stress and Aβ-induced toxicity 
(Greeve et al., 2000). Furthermore, seladin-1 was linked to tau-related neuronal degeneration 
in AD, showing a close inverse correlation between the seladin-1 expression level and the 
presence of NFTs, neuritic plaques and paired helical filaments in temporal cortices of AD 
cases when compared to non-demented subjects (Iivonen et al., 2002). More recent findings 
give evidence of an interaction between seladin-1 and the tumor suppressor protein p53 (Wu 
et al., 2004). Following oncogenic and oxidative stress, Wu et al. could show that seladin-1 
binds to p53, thus displacing the E3 ubiquitin ligase Mdm2 from p53, resulting in p53 
accumulation. These data implicate an unanticipated role for seladin-1 in integrating cellular 
response to oncogenic and oxidative stress (Wu et al., 2004). It remains to be determined 
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whether the potential function of seladin-1 described above is associated with its DHCR24-
function in cholesterol biosynthesis. 
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1.3 AIM OF THE STUDY 
Given the fundamental role of cholesterol in maintaining the integrity of physiological 
membranes, one important objective of this thesis was the analyses of the consequences of 
cholesterol depletion on membrane organization and DRM formation in vivo. To this aim, we 
employed mice depleted of one dhcr24 allele (heterozygous DHCR24+/- mice), as a model for 
a moderate cholesterol reduction of about 25%, and knock-out mice (DHCR24-/-) depleted of 
both alleles, to study a chronic cholesterol deficiency. This was attempted applying various 
methods such as sucrose gradient fractionation, protein flotation profiling and lipid analyses. 
In order to assess the functional relevance of the observed alterations in DRM composition, 
we studied plasmin activity, APP processing, Aβ generation and signal transduction pathways 
as important examples of membrane-dependent cellular events. Moreover, we tried to evaluate 
whether cholesterol can be functionally substituted in vivo. Age-dependent accumulation of 
desmosterol in adult DHCR24-/- mice allowed us to examine, whether cholesterol can be 
physically and functionally replaced by its direct precursor.  
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2. METHODS 
 
2.1 MICE 
A heterozygous breeding pair with targeted depletion of one dhcr24 allele was received from 
Dr. E. Feinstein (Quark Biotech, Inc.). Mice were bred to a pure FVB background and 
genotyped as described (Wechsler et al., 2003). In brief, DNA was extracted of tail biopsies 
from three week-old mice using the DNeasy tissue kit (Qiagen). PCR reaction was performed 
using two dhcr24 specific primers (5’TCGCTGGCCGTGTGCGCGCT-3’ and 5’-
ATCCCCACTCCCACGCCCATT-3’) designed to amplify a 312 bp fragment from the 
normal allele, and one primer specific for the Neomycin cassette, inserted in the first exon (5’-
GATGGATTGCACGCAGGTTC-3’), designed to amplify a 969 bp fragment when used in 
combination with the upstream located dhcr24 specific primer. The PCR reaction was carried 
out at the following conditions, using all three primers simultaneously: denaturation 2 min 
94°C; 30 cycles of 45 sec 60°C; 2 min 72°C; 1 min 94°C. Reactions were completed by 10 
min incubation at 72°C. All animal experiments and husbandry were performed compliant 
with national guidelines.  
 
2.2 ANTIBODIES, WESTERN BLOTS AND QUANTIFICATION 
Monoclonal anti-flotillin 1 (clone 18, Transduction Laboratories), monoclonal anti-cellular 
prion protein (Prpc) (POM-1, kindly provided by Dr. A. Aguzzi, University of Zurich), 
monoclonal anti-transferrin receptor (TfR) (Clone CD-71, Santa Cruz Biotechnology Inc.), 
polyclonal anti-C-terminal APP (Sigma), monoclonal anti-N-terminal APP (22C11, 
Chemicon) and monoclonal m3.2  anti-APP antibody binding within residues 1-15 of mouse 
Aβ, recognizing mouse full length APP, sAPPα and the Aβ peptide (kindly provided by Dr. 
Paul M. Mathews, New York University) were used for Western blot analysis of APP 
processing products and sucrose gradient fractions. For signal transduction analyses anti-p-
ERK Thr177/Thr160 (sc23759-R, Santa Cruz), anti-p-SAPK Thr183/Tyr185 (#9251, cell 
signaling), anti-GSK Ser9 (sc11757, Santa Cruz), anti-AT8 (Innogenetics), anti-p-Akt1/2/3 
Ser473 and Thr 308 (sc7985-R and sc-16646-R Santa Cruz), anti-p-p38 Thr180/Tyr182 
(#9211, cell signaling) and anti-RhoA 119 (sc-179, Santa Cruz) antibody were used for 
Western blot analysis. Monoclonal anti-β-actin (Abcam) and anti-GAPDH (Biodesign) 
antibodies were used as internal loading controls and for normalization of densitometric 
analysis of the immunoreactive bands. All antibodies were diluted in 5% fat-free milk 
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(Migros) in 35 mM Tris–HCl (pH 7.4) and 140 mM NaCl (TBS buffer). For Western blotting, 
16% Tris-Glycine polyacrylamide–SDS gels and Novex 10-20% gradient Tricine gels 
(Invitrogen) were used. Proteins were transferred to a nitrocellulose membrane (0.45 mm 
pore; Bio-Rad). Species specific peroxidase-conjugated secondary antibodies and the ECL 
detection method (all from Amersham) were subsequently used. Western blot analyses were 
performed in 4-5 mice of each genotype and age-group. Quantification of immunoreactive 
bands was carried out by densitometry of the scanned films under conditions of non-saturated 
signals using the ImageJ software.  
 
2.3 TISSUE PREPARATION 
Mice were perfused transcardially under deep anesthesia (ketamin 100 mg, xylazine 5 mg/kg 
bodyweight, i.p.) using a peristaltic pump. Perfusion was performed initially with PBS pH 7.4 
for 10-15 minutes on ice. For histological analyses, mice were subsequently perfused with 4% 
PFA. Brains were frozen or immersion-fixed in 4% PFA overnight at 4°C.  
 
2.4 QUANTITATIVE RT-PCR 
Total RNA was prepared from SH-SY5Y cells (n=4 of each condition) and half brains of mice 
(n=5 each) with TRIZOL (Invitrogen), DNase treated using RNase-Free DNase Set (Quiagen) 
and quality checked on a 2% Agarose gel. 2 µg were reversely transcribed into cDNA with 
the Transcriptor First Strand cDNA Synthesis Kit (Roche) and 1:4 diluted. Real-time PCR 
was performed in triplicates using 2 µl of cDNA in Full Velocity SYBR Green QPCR Master 
Mix (Stratagene) reagent (25 µl/well) according to the manufacturer’s protocol. Primers were 
used at a final concentration of 500 nM. Sequences of the primers used for real-time PCR are 
listed in Table 1. To advance specificity of the reaction, primers were designed spanning 
genomic introns. Specificity of the reaction was also confirmed by agarose gel-electrophoresis 
of the PCR products. Relative mRNA levels were calculated according to the comparative 
threshold cycle (∆∆CT) method (Ohyama et al., 2006). The housekeeping genes 
Glycerinaldehyd-3-phosphate-Dehydrogenase (gapdh) and β-actin were used as reference 
genes for analyses in mouse brains, and gapdh and phosphoglucokinase (pgk) were used as 
reference genes for SH-SY5Y cell analyses.  
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Table 1 Oligodeoxyribonucleotide primers used for quantitative real-time PCR analysis 
    
Gene Species Forward (5’-3’) Reverse (5’-3’) 
dhcr24 mouse CATCGTCCCACAAGTATG CTCTACGTCGTCCGTCA 
hmgcr mouse CCGGCAACAACAAGATCTGTG ATGTACAGGATGGCGATGCA 
fas mouse TCCTGGAACGAGAACACGATC ATTTCCTGAAGTTTCCGCAGC 
srebp1c mouse GGAGCCATGGATTGCACATT GGCCCGGGAAGTCACTGT 
srebp2 mouse TGAAGCTGGCCAATCAGAAAA ATCACTGTCCACCAGACTGCC 
β-actin mouse TACTCTGTGTGGATCGGTGGC TGCTGATCCACATCTGCTGG 
gapdh mouse GGCATCTTGGGCTACACTGAG CGAAGGTGGAAGAGTGGGAG 
srebp1c human TGCGTCGAAGCTTTGAAGG AGGTCGAACTGTGGAGGCC 
hmgcr human CCACGTGAATGGCCCTAGAA TTTCAGTCACCAACCTCCTGG 
fas human GAACTCCTTGGCGGAAGAGAA GGACCCCGTGGAATGTCAC 
pgk human TGAAGGACTGTGTAGGCCCAG TTCTTCCTCCACATGAAAGCG 
    
 
 
2.5 HISTOLOGY 
After extensive washing, the fixed tissue fragments were dehydrated through a graded series 
of ethanol solutions followed by xylol incubation and embedded in paraffin before making 
histological sections. Specimens (5 µm) were washed in xylene and dehydrated according to 
standard protocols. Sections were stained with hematoxylin and eosin (H/E) and used for a 
myelin stain (Luxol fast blue) according to standard protocols. Apoptotic cells were detected 
performing immunohistochemistry with an antibody against cleaved caspase-3 Asp175 
(#9661, cell signaling) following the manufacturer’s instructions. Terminal deoxynucleotidyl 
transferase mediated dUTP nick end labeling assay (TUNEL) was performed according to the 
manufacturer’s protocol (Roche). 
 
2.6 BRAIN SAMPLE PREPARATION 
Mouse brains were homogenized in a Tris-Buffer (20 mM Tris, 137mM NaCl, pH 7.6) 
containing 2% SDS with protease inhibitors in a dounce homogenizer for 5 minutes on ice. 
The samples were centrifuged at 100,000 g for 1 hour at 4°C to pellet the insoluble debris. 
The supernatant was considered as total homogenate. For membrane preparations mouse 
brains were homogenized in 25 mM MES pH 7.0, 5 mM DTT, 2 mM EDTA and protease 
inhibitor without detergent in a dounce homogenizer on ice and centrifuged for 2 minutes at 
2000 g to pellet the debris. Supernatants were centrifuged at 100,000 g for 1 hour at 4°C. 
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Pellets were considered as total membrane. Protein concentration was quantified using the DC 
protein assay (BIORAD).  
 
2.7 SUCROSE GRADIENT FRACTIONATION 
Detergent extraction and DRM isolation were performed as described (Crameri et al., 2006). 
In brief, mouse brain extracts were incubated for 1 hour at 4°C in 1% Triton X-100, 25 mM 
MES pH 7.0, 5 mM DTT, 2 mM EDTA and protease inhibitor. The extracts were mixed with 
90% sucrose prepared in MBS buffer (25 mM MES pH 7.0, 150 mM NaCl and CLAP) over 
layered with a step gradient of 35% and 5% sucrose in MBS. After centrifugation at 100,000 g 
for 18 hours at 4°C, fractions 4-6 were identified as the DRM fraction by the presence of the 
DRM markers flotillin-1 and Prpc in the control samples. Analyses were performed in three 
mice of each genotype and age-group. 
 
2.8 LIPID ANALYSIS  
Lipids were extracted from membrane pellets according to the Bligh-Dyer method using 
chloroform/methanol (Bligh and Dyer, 1959). Sphingomyelin, the ganglioside GM1 and 
phospholipids were determined as described (Crameri et al., 2006). Briefly, sphingomyelin 
was analyzed by thin-layer chromatography (TLC), GM1 by slot-blot using cholera toxin 
subunit B linked to a peroxidase (Sigma) and phospholipids were determined using the 
Phospholipid B kit (WAKO) according to the manufacturer’s protocol. Analyses were 
performed in four mice of each genotype and age-group. 
 
2.9 STEROL ANALYSIS 
The dissected cortex specimens were dried to constant weight in a Speedvac® (Servant 
Instruments, Inc., Farmingdale, NY, USA). Sterols were extracted by chloroform/methanol 
(2:1 v/v). 50 µg 5α-cholestane (Serva Electrophoresis GmbH, Heidelberg, Germany) (50 µL 
from a stock solution of 5α-cholestane in cyclohexane; mg/mL), 1 µg epicoprostanol (Sigma-
Aldrich, Munich, Germany) (10 µL from a stock solution epicoprostanol in cyclohexane; 100 
µg/mL) were added to 500 µl of extract as internal standards. The organic solvents were 
evaporated under nitrogen gas at 60°C. After alkaline hydrolysis with 1 N sodium hydroxide 
in 90 % ethanol for one hour at 50°C the sterols were extracted twice with 3 mL cyclohexane. 
The combined organic phases were dried under nitrogen at 60°C. The residue was dissolved 
in 500 µL n-decan and the sterols were derivatised to trimethylsilyl- (TMSi) ethers by adding 
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20 µL of TMSi-reagent (pyridine: hexamethyldisalazane-trimethylcholorosilane; 9:3:1, by 
volume; all reagents were supplied by Merck) into each micro-vial and incubated for 1h at 
60°C. The corresponding trimethylsilylethers of each sterol was determined by gas 
chromatography- flame ionisation detection as described previously (Lutjohann et al., 2004). 
Analyses were performed in three mice of each genotype at three weeks of age and four mice 
of each group at 16 weeks of age. In addition, total sterols were measured using the Amplex 
Red Cholesterol Kit (Molecular Probes/Invitrogen). We established that this kit detects 
cholesterol and desmosterol with the same sensitivity by using dilution series of commercially 
available sterols (Sigma). For total sterol determination, lipids were isolated from each 
sucrose gradient fraction and from primary neurons as described (Bligh and Dyer, 1959), 
solubilized in DMSO and applied to the assay.  
 
2.10 ELISA  
Murine Aβ ELISA was performed as previously described (Crameri et al., 2006; Fukumoto et 
al., 2002). In brief, hemi brains were homogenized in a buffer containing 100 mM Tris and 
150 mM NaCl pH 7.4 and proteinase inhibitors (Roche). Total brain extracts containing 
soluble and membrane bound Aβ and supernatants of primary neurons were analyzed by a 
modified sandwich ELISA that specifically detects either Aβ40 or Aβ42 (Takeda, Japan) 
according to the provider’s protocol. Aβ was captured with a specific anti-Aβ antibody 
(BNT77). Aβ species ending in residue 40 or 42 were measured using horseradish peroxidase-
coupled monoclonal antibodies specific for Aβ40 (HPR-conjugated BA27) and Aβ42 (HPR-
conjugated BC05) sequence. Analyses were performed for four mice of each genotype and 
age-group and in two independent experiments for primary neurons with four biological 
replicates of each genotype.  
 
2.11 PLASMINOGEN BINDING AND PLASMIN ACTIVITY 
200µg of freshly prepared membrane extracts from mouse brains (n=3 each) and SH-SY5Y 
cells were resuspended in Hank’s balanced saline solution (HBSS) and 0.1% Ovalbumin 
(Sigma) and were placed in a 96 multiwell plate in the presence of 2 mM chromogenic 
peptide to measure endogenous plasmin activity. In parallel experiments plasminogen binding 
to cellular membranes was determined by addition of 2 µM human plasminogen to the same 
extracts. Plasmin enzymatic activity was assayed using the chromogenic substrate S-2251 
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(Chromogenix) specific for this protease. Absorbance was measured at 37°C and 405 nm in 
an ultra microplate reader Elx808iu (BioteK instruments, INC) every 5 minutes. 
 
2.12 SECRETASE ACTIVITY ASSAYS 
Secretase activities were measured using α-, β- and γ-secretase activity Kits (R&D systems). 
These assays rely on the cleavage of secretase-specific peptides that are conjugated to the 
reporter molecules EDANS and DABCYL. In the uncleaved form the fluorescent emissions 
from EDANS are quenched by the physical proximity of the DABCYL moiety which exhibits 
maximal absorbance at the same wavelength (495 nm). Cleavage of the peptide by the 
secretase physically separates the EDANS and DABCYL allowing for the release of a 
fluorescent signal. Reactions were carried out according to the manufacture’s instructions 
using provided buffers. In brief, half brains (n=5 each) were homogenized in cell extraction 
buffer to a final concentration of 2 mg/ml. Homogenates were incubated on ice for 10 minutes 
and centrifuged at 10,000 g for 1 minute. Supernatant, 2x reaction buffer and substrates were 
added to each well, gently mixed and incubated in the dark at 37°C for 1-2 hours. The plate 
was read in a fluorescent micro plate reader using 355 nm wavelengths for excitation and 510 
nm for emission with a 495 nm cutoff.  
 
2.13 PRIMARY NEURONAL CULTURES 
Primary neuronal cultures were prepared from wildtype, DHCR24+/- and DHCR24-/- embryos 
at E13-16. The cortex was dissected, and kept in ice-cold Hank's balanced salt solution 
(HBSS; 10 mM HEPES, pH 7.3) (Invitrogen). Meninges were removed and the cortical 
tissues were incubated for 10 minutes in 2.4 U/ml Dispase (Roche) and 0.2 mg/ml 
deoxyribonuclease (Sigma) and then dissociated to single cells by gentle trituration. The cell 
suspension was mixed with Neurobasal-Medium supplemented with B27 (Invitrogen), 0.5 
mM glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin. The cell suspension was 
centrifuged at 310 g for 3 minutes and the resulting pellets were resuspended in the medium 
described above and plated onto polyornithin/laminin (Sigma) coated 12-well plates with one 
coated glass cover slip for immunocytochemical staining in each well. The cells were cultured 
in a CO2 incubator (5% v/v, 37°C) for 3-5 days. For Western blot analysis of sAPPα, the 
supernatant was collected, acetone precipitated and dissolved in loading buffer. For detection 
of Aβ in supernatants of primary neurons, cells were grown in 12-well plates in cholesterol- 
and serum-free medium complemented with B27 (Invitrogen) for 3 days in vitro. Medium was 
removed, cells were washed with PBS and overlaid with 350 µl of fresh serum-free medium. 
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After 24 hours, 150 µl of the supernatant was used for ELISA without further processing. For 
Western blot analysis of full length APP primary neurons were homogenized in a Tris-Buffer 
containing 2% SDS with protease inhibitors. Analyses were performed in two independent 
experiments with four biological replicates of each genotype. 
 
2.14 IMMUNOCYTOCHEMISTRY 
Neurons were fixed with 4% PFA for 10 minutes at room temperature, blocked and 
permeabilized with 5% horse serum containing 0.1% Triton X-100 for 2 hours. Anti-Map2 
antibody and anti-GFAP antibody (both from Sigma) were used to determine the percentage 
of neurons and astrocytes according to the manufacturer’s instructions. Species specific 
fluorescence-labeled secondary antibodies (Amersham) were diluted in blocking buffer and 
cells were stained for 2-4 hours in the dark. The cells were washed and embedded in Moviol 
(Merck).  
 
2.15 CELL CULTURE 
SH-SY5Y cells were cultured in DMEM NUT-F12 medium (Invitrogen) containing 10% 
foetal calf serum (FCS), 5% horse serum (HS) and 5000U/ml penicillin and 5000µg/ml 
streptomycin. Sterols were dissolved in 95% EtOH. Cells were grown in serum-free media 
containing 10 µg/ml lanosterol, 10 µg/ml desmosterol, 10 µg/ml lanosterol plus 10 µg/ml 
desmosterol, or control reagent only (95% EtOH) for four days. After sterol treatment of SH-
SY5Y cells and before Aβ measurement in the medium of primary neurons, the viability of 
the individual cultures was determined using the MTT (Sigma) and the LDH assay (Sigma) 
according to the manufacturer’s instructions. For desmosterol addition and cholesterol 
reduction in SH-SY5Y cells, desmosterol and methyl-β-cyclodextrin (Sigma) were complexed 
as described previously for cholesterol (Klein et al., 1995). These complexes containing 0.3 
mM desmosterol were added to the medium of SH-SY5Y cells at a final 1:10 dilution together 
with 2 µg/ml free desmosterol and incubated for 1h at 37°C. To moderately reduce cholesterol 
from SH-SY5Y cells, the cells were incubated for 48 hours with 0.4 µM mevilonin (Sigma) 
and 1 mM methyl-β-cyclodextrin to extract 30% cholesterol as described previously (Abad-
Rodriguez et al., 2004). The incorporation of desmosterol was monitored by TLC using pure 
desmosterol (Sigma) as standard. Cholesterol reduction in mevilonin and methyl-β-
cyclodextrin treated cells was monitored by the Amplex red kit (Molecular Probes/Invitrogen) 
as described above. Cell viability after these treatments was not affected, as determined as 
described above. 
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2.16 STATISTICAL ANALYSIS  
Data were collected by investigators blinded to the experimental setup and were statistically 
analyzed by non-parametric Mann-Whitney U-test. In all graphs, mean±SEM (standard error 
of the mean) are shown unless otherwise noted. In tables, mean±SD (standard deviation of the 
mean) are shown. p-values <0.05 were considered to be statistically significant. *p<0.05, 
**p<0.01. 
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3. RESULTS 
 
3.1 VIABILITY AND NEUROPATHOLOGICAL STATUS OF DHCR24-/- MICE  
DHCR24 knock-out mice (DHCR24-/-) were born at a lower frequency than expected (10-
17%) and were about 25% smaller in size than their heterozygous (DHCR24+/-) and wildtype 
(wt) littermates, as previously described (Wechsler et al., 2003). DHCR24+/- littermates 
showed no obvious phenotype. After backcrossing DHCR24+/- mice (C57BL/6x129SvEv) to a 
pure FVB background the frequency of born knock-out mice from heterozygous matings was 
increased to an almost normal rate (15-20%). To ensure surviving of the visibly smaller 
knock-out mice, the number of littermates was decreased to 2-3 mice per mating.  
 
Figure 4 Neuropathological analyses of three week-old wt and DHCR24 depleted mice. Histolgical H/E 
stainings of cortical (A) and hippocampal (B) sections and Luxol fast blue stainings of different cortical areas (C 
and D) revealed no structural or morphological differences between the three genotypes.  
 
Under these conditions maternal care was ensured. The knock-out mice were able to suck, 
determined by an evident full stomach, and developed normally, although with poorer growth 
characteristics. While some DHCR24-/- mice reached about normal weight 10-12 weeks after 
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birth, the average weight of knock-out mice was below the level of wildtype and heterozygous 
littermates, as previously described (Wechsler et al., 2003). Neuropathological examinations 
of mice at the age of three weeks and four months applying different histological methods 
such as hematoxylin/eosin (H/E) and myelin staining (Luxol fast blue) revealed that there 
were no detectable morphological or structural differences between wildtype, heterozygous 
and knock-out mice (Figure 4). These analyses were confirmed by Dr. vet. Monika Hilbe at 
the Tierspital in Zurich, who analyzed brains from mice of all three genotypes at different 
ages (two days, three weeks and four months). Furthermore, no differences in apoptotic events 
were detected in brains of DHCR24-/- mice as revealed by TUNEL and cleaved caspase-3 
staining of histological brain sections (data not shown).  
 
 
3.2 YOUNG DHCR24 DEPLETED MICE 
It was shown that cholesterol biosynthesis is high in the brain of newborn mammals but is 
reduced during postnatal development, while it levels off about 2-3 weeks after birth (Ohyama 
et al., 2006). We therefore examined the brains of three week-old (young) wt, DHCR24+/- and 
DHCR24-/- mice. 
 
3.2.1 Brain sterol synthesis and elimination  
To eventually produce cholesterol from lanosterol a series of enzyme reactions is required. 
DHCR24 reduces the C24 double bond of all sterols of the Bloch-pathway, starting from 
lanosterol as the first substrate. Desmosterol is the ultimate precursor of cholesterol and the 
last possible substrate for DHCR24 of the Bloch-pathway. The synthesis of sterols of the 
Kandutsch-Russel pathway including lathosterol and cholesterol is essentially dependent on 
DHCR24 (see Figure 3 in chapter 1.2.1). We analyzed the sterol distribution in brains of 
young wt, DHCR24+/- and DHCR24-/- mice using gas-chromatography/mass-spectrometry. 
With DHCR24 depletion sterols of the Bloch-pathway were accumulating, whereas 
components of the Kandutsch-Russel pathway were reduced (Figure 5A and Table 2). 
Cholesterol was significantly reduced in brains of DHCR24+/- mice (77±11%, p=0.016) and 
dramatically diminished in DHCR24-/- brains (4.2±1%, p=0.025) compared to wt mice. The 
ultimate substrate of DHCR24, desmosterol, was markedly increased in DHCR24+/- brains 
(383±138%, p=0.004) and tremendously increased in brains of DHCR24-/- mice (4783±56%, 
p=0.025). Whereas lanosterol, the first substrate of DHCR24, was moderately elevated with 
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DHCR24 depletion (126±44%, p=0.167 in DHCR24+/- brains and 189±44%, p=0.025 in 
DHCR24-/- brains, respectively), lathosterol and the brain specific catabolic product of 
cholesterol, 24S-OH-cholesterol, were significantly decreased in brains of DHCR24+/- mice 
(72±13%, p=0.042 and 75±10%, p=0.028, respectively) and were virtually absent in knock-
out mouse brains (6.3±2%, p=0.025 and 4.3±2%, p=0.025, respectively). 
The major sterol in wt brains was cholesterol, accounting for over 99% of all sterols, while 
desmosterol represented less than 1% of all sterols in wt brains (Figure 5B and Table 2). Since 
desmosterol is the last sterol of the Bloch-pathway and its reduction is solely catalyzed by 
DHCR24, this sterol was increased in DHCR24+/- brains and greatly accumulated in brains of 
knock-out mice. However, compared to the total amount of cholesterol in brains of young wt 
mice, desmosterol concentration reached about 8% in DHCR24+/- brains, in DHCR24-/- mice 
about 50% of wt cholesterol levels; therefore the amount of total sterols was reduced by 
approximately 15% in brains of DHCR24+/- mice, presenting a model of moderate cholesterol 
reduction with slightly increased levels of desmosterol. Total sterols in brains of DHCR24-/- 
mice were reduced by 47%, while desmosterol accounted for over 95% of these sterols. The 
small proportion of cholesterol in DHCR24-/- mice was most probably maternal cholesterol 
that traversed the placenta and did not derive from de novo cholesterol biosynthesis. All 
together, these data clarify the role of DHCR24 in brain sterol biosynthesis and suggest that 
other enzymes of the two pathways, for example DHCR14, are not capable of taking over the 
reductase function of DHCR24, as proposed earlier (Peri et al., 2005).  
 
Table 2 Brain concentrations (ng/mg wet weight; mean ±SD) of cholesterol, desmosterol, lanosterol, lathosterol 
and 24S-OH-cholesterol of young (three week-old) wt, DHCR24+/- and DHCR24-/- mice  
      
Genotype Lanosterol Desmosterol Lathosterol Cholesterol 24S-OH-Chol 
      
wt 37±7       567±84 391±87 59,623±7,305 340±53 
DHCR24+/- 46±16    2,172±777** 281±49* 45,730±5,962* 256±33* 
DHCR24-/- 70±16* 27,141±47*   25±1*   2,496±66*   15±7* 
      
*p<0.05, **p<0.01 vs. aged-matched controls. Exact p-values are given in the text 
 
In conclusion, these data reveal that young DHCR24+/- mice demonstrate a model for a 
moderate cholesterol reduction of about 25%, whereas DHCR24-/- mice present a model that 
is entirely devoid of cholesterol but accumulates desmosterol over time. Wechsler et al. could 
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show that desmosterol levels already increased during embryonic development of DHCR24-/- 
mice (Wechsler et al., 2003). Our findings support this theory of desmosterol accumulation 
and suggest that there is no efficient catabolism of desmosterol in the murine brain.  
control
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Figure 5 Sterol distribution and differential gene expression in brains of wt and DHCR24 depleted mice. (A) 
Lanosterol was moderately increased with DHCR24 depletion, while desmosterol accumulated gradually in 
DHCR24+/- and DHCR24-/- brains. Cholesterol, lathosterol and 24S-OH-chol were significantly reduced in 
DHCR24+/- brains and virtually absent in DHCR24-/- brains. Sterol levels in wt brains were considered as 100%. 
(B) In wt and DHCR24+/- brains cholesterol was the major sterol, accounting for almost 99% of all sterols, while 
desmosterol was the predominant sterol in DHCR24-/- brains. Absolute desmosterol concentrations in young 
DHCR24-/- brains were only half of the cholesterol concentrations in wt mice. (C) Expression analyses of genes 
involved in brain cholesterol and lipid homeostasis were determined by real-time PCR. Elevations in fas and 
srebp1 expression and reduced hmgcr expression in DHCR24-/- brains were apparent, whereas no significant 
effect was observed for srebp2 in DHCR24 depleted brains. DHCR24 expression was significantly reduced in 
DHCR24+/- brains and DHCR24 mRNA was absent in DHCR24-/- brains. Data were normalized to the mean 
value of the two housekeeping genes gapdh and β-actin. (D) SH-SY5Y cells were treated with lanosterol, 
desmosterol and a combination of both sterols. Lanosterol significantly reduced hmgcr expression, also in 
combination with desmosterol, while desmosterol alone did not alter hmgcr expression. Sterol treatment did not 
affect srebp1 expression. Relative mRNA levels of the respective genes in wt brains were considered as 100% 
(*p<0.03, **p<0.009). 
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3.2.2 Differential expression of cholesterol related genes  
To identify changes in gene expression that are associated with cholesterol depletion, we 
isolated total RNA from hemi brains of young DHCR24+/-, DHCR24-/- and wt littermates and 
performed real-time PCR experiments (Figure 5C). Expression analysis of genes involved in 
cholesterol and fatty acid biosynthesis revealed a trend towards an increased expression of 
fatty acid synthase (fas) in DHCR24+/- brains (119±6.8%, p=0.076), while fas expression was 
significantly increased in DHCR24-/- brains (177±17.1%, p=0.027). Expression of the sterol-
regulatory element binding protein 1 (srebp1) was unchanged in DHCR24+/- brains, but highly 
elevated in DHCR24-/- brains (158±8.6%, p=0.014), whereas expression of srebp2 was 
unchanged with DHCR24 depletion compared to controls. Expression of the hmgcr gene, 
encoding for the rate-limiting enzyme in cholesterol biosynthesis, showed a trend towards a 
reduction in DHCR24+/- brains (81.9±12.5%, p=0.072) and was significantly reduced in brains 
of young DHCR24-/- mice (62.1±5.4%, p=0.002).  
Analyses of dhcr24 expression revealed a gene dose-dependent effect in DHCR24+/- mice 
(46.3±13.6%, p=0.009), explaining the reduced cholesterol levels in heterozygous brains and 
the increase of desmosterol in these mice. DHCR24 mRNA was not detectable in DHCR24-/- 
mice. The expression of the housekeeping genes gapdh and β-actin was not altered between 
the three genotypes (not shown). Relative mRNA levels of the respective genes were 
normalized to the mean value of both housekeeping genes. 
Analyses of sterol distribution and expression of the rate-limiting enzyme HMGCR suggest a 
possible feedback mechanism from early Bloch-sterols such as lanosterol on hmgcr 
expression. Previous studies showed that lanosterol and its naturally occurring oxygenated 
derivative oxylanosterol can influence cholesterol biosynthesis and HMGCR activity, by 
mediating post-transcriptional modification and stimulating the degradation of HMGCR 
(Panini et al., 1992; Panini et al., 1986; Song et al., 2005). Therefore, we treated SH-SY5Y 
neuroblastoma cells with lanosterol, desmosterol and a combination of both sterols (5 µg/ml 
each in 95% ethanol) and determined hmgcr expression in these cultures (Figure 5D). 
Lanosterol treated cultures and cultures treated with both sterols showed a significant decrease 
in hmgcr expression compared to control cultures that were treated with 95% ethanol, while 
desmosterol treatment alone did not alter hmgcr expression. These results suggest that 
lanosterol or its naturally occurring oxygenated derivative might be part of a feedback 
mechanism on cholesterol biosynthesis, thus regulating the expression of the rate-limiting 
enzyme HMGCR. Treatment of SH-SY5Y cells with sterols as described above did not reveal 
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any differences in expression of srebp1 (Figure 5D) and fas (data not shown), suggesting that 
cholesterol paucity might be responsible for the observed elevation of srebp1 and fas 
expression in DHCR24-/- brains, rather than the increase of lanosterol or desmosterol.  
 
3.2.3 Membrane organization: DRM protein and lipid composition  
Given the fundamental role of cholesterol in maintaining the integrity of physiological 
membranes and lateral membrane domains we next tested whether changes in dhcr24 
expression affect the protein and lipid composition of DRMs. To this aim, total brain extracts 
from young wt, DHCR24+/- and DHCR24-/- mice were incubated with 1% Triton X-100 at 4°C 
and centrifuged in a sucrose gradient. This procedure allows the separation of detergent-
insoluble membrane portions (DRMs) from soluble parts of the membrane. Ten fractions were 
collected from the top of each tube, while the first fraction was discarded. Fractions 4-6 were 
identified as DRM fractions by the presence of the raft markers cellular Prion protein (Prpc), 
flotillin-1 and the raft-specific ganglioside GM1 in the control samples. Determination of the 
total amount of protein in each fraction revealed significantly lower protein levels in the DRM 
fractions with DHCR24 depletion (Figure 6A). While in wt mice 20.2±2.5% of total protein 
was found in DRM fractions, this percentage was significantly decreased in DHCR24+/- 
(13.9±2.7%, p=0.02) and DHCR24-/- mice (3.1±0.8%, p=0.025). Analysis of the flotation 
profile of Prpc revealed significantly less Prpc in DRM fractions of the DHCR24 depleted 
mice (Figure 6B and Table 3). A similar pattern was observed analyzing the flotation profile 
of another raft marker, flotillin-1, that was significantly reduced in DRM fractions of 
DHCR24+/- mice and even absent in these fractions in DHCR24-/- brains (Figure 6C and Table 
3).  
Table 3 Percentages of the total amounts of the respective proteins and lipids (set as 100%) in brain DRM 
sucrose gradients fractions of young (three week-old) wildtype, DHCR24+/- and DHCR24-/- mice.  
      
Genotype Prpc flotillin-1 Cholesterol SPM GM1 
      
wt 40.5±5% 12.3±1% 53.5±9% 37.6±6% 71.8±6% 
DHCR24+/- 12.5±5% p=0.02 5.1±2% p=0.021 36±7% p=0.043 17±7%   p=0.043 62±3%   p=0.048 
DHCR24-/-  3.5±1% p=0.025 - -  6.0±3% p=0.025  2.4±1% p=0.025 
      
p-values vs. aged-matched wildtype mice 
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The total protein level of both raft markers in brain homogenates were similar in all three 
genotypes (Figure 6E), suggesting that cholesterol depletion influenced merely the subcellular 
distribution of these proteins, while total protein levels were not affected.  
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Figure 6 Protein analyses of sucrose gradient fractions. (A) Percentage of total protein in DRM fractions 4-6 
were significantly reduced with DHCR24 depletion. Western blot analyses of flotation profiles of Prpc (B) and 
flotillin-1 (C) revealed an altered subcellular distribution of the two raft marker with DHCR24 depletion, while 
no differences were detected in the distribution of the non-raft marker TfR (D). Western blots on the left show 
representative examples. Graphs on the right show the distribution of Prpc, flotillin-1 and TfR in each fraction as 
percentage of the total amount of the respective protein along the entire gradient. (E) Total levels of Prpc and 
flottillin-1 were unchanged in brain homogenates of all three genotypes. GAPDH was used as loading control 
(*p<0.03). 
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The non-raft protein Transferrin receptor (TfR) remained in the heavy fractions to a 
comparable extent in brains of all three genotypes (Figure 6D).  
Analysis of the distribution of membrane constituents in soluble (8-10) and DRM fractions (4-
6) revealed a significant decrease of total sterols in DRM fractions of DHCR24+/- mice 
(82±1.7%, p=0.043, Figure 7A). In DHCR24-/- mice, total sterols were significantly reduced 
in soluble fractions 8-10 of the sucrose gradients (47.8±14.3%, p=0.021), and even below 
detection level in their DRM fractions (Figure 7A). Because endogenous desmosterol levels 
represent only about 1% of total sterols in wt brains (Table 2), we conclude that cholesterol 
accounts for the majority of total sterols in wt and DHCR24+/- soluble and DRM fractions. In 
contrast, the detected amount of sterols in DHCR24-/- brains is most probably merely 
desmosterol, the predominant sterol in these mice. Analyses of sucrose gradient fractions by 
TLC for cholesterol (Figure 7B and Table 3) confirmed these findings, revealing a significant 
reduction of cholesterol in DRM fraction of DHCR24+/- brains. Cholesterol was not detectable 
by TLC of sucrose gradient fractions of DHCR24-/- brains. These data suggest that moderate 
cholesterol depletion in DHCR24+/- mice mainly affected cholesterol pools in lateral 
membrane domains such as DRMs, whereas cholesterol levels in soluble membrane fractions 
were apparently not disturbed. 
 
Lipid analyses of sucrose gradient fractions revealed major changes in the distribution of 
sphingomyelin (SPM) and the ganglioside GM1 in DHCR24+/- and DHCR24-/- brains 
compared to wt controls (Figure 7C,D and Table 3). Both lipids were significantly reduced in 
DRM fractions with DHCR24 depletion, whereas the total brain levels were similar in all 
three genotypes (data not shown). Analysis of total brain homogenates also revealed no 
differences in the levels of phospholipids between the three genotypes (Figure 7E). These 
results show that the distribution of raft proteins, sterols and lipids is significantly altered with 
moderate cholesterol depletion in young DHCR24+/- brains. Moreover, these data point out 
that total cholesterol deficiency in DHCR24-/- mice has deleterious effects on membrane 
organization, challenging the very existence of lipid rafts in these mice.  
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Figure 7 Lipid analyses of sucrose gradient fractions. (A) Measurement of total sterols in soluble (8-10) and 
DRM (4-6) fractions revealed a significant decrease of sterols in DRM fractions of DHCR24+/- brains. The level 
of total sterols was significantly reduced in soluble fractions of DHCR24-/- brains, while sterols were below 
detection level in DRM fractions of these mice. Data from wt mice were considered as 100%. TLC of cholesterol 
(B) and SPM (C) distribution in sucrose gradient fractions showed a significant reduction of cholesterol in DRM 
fractions with DHCR24 depletion. (D) Slot blot analyses of GM1 distribution in sucrose gradient fractions 
revealed a significant reduction of this ganglioside in DRM fractions of DHCR24 depleted brains. Pictures on the 
left show representative examples. Graphs on the right show the distribution of cholesterol, SPM and GM1 in 
each fraction as percentage of the total amount of the respective lipid along the entire gradient. (E) Phospholipid 
concentration in total brain homogenates was not altered between the three genotypes. Data from wt mice were 
considered as 100% (*p<0.05). 
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3.2.4 Analyses of DRM-dependent functions: plasminogen binding and plasmin 
activation  
To evaluate the functional consequences of the observed disturbances in DRM composition in 
DHCR24 depleted mice, we analyzed plasmin activity in plasma membranes of DHCR24+/- 
and DHCR24-/- mouse brains. Plasmin activity is regulated by plasminogen activators, 
plasminogen activator inhibitors and plasmin inhibitors (Collen, 1999). In addition, plasmin 
generation is dependent on the binding of plasminogen to the plasma membrane (Plow et al., 
1995). This occurs via the association with molecules such as α-enolase (Miles et al., 1991), 
annexin II (Hajjar and Acharya, 2000), amphoterin (Parkkinen and Rauvala, 1991) or the 
ganglioside GM1 (Miles et al., 1989). Experimental data point to DRMs as the sites where the 
plasminogen binding and activation take place. Moreover, plasminogen-binding molecules are 
enriched in rafts of neurons (Ledesma et al., 2003), and plasmin is almost exclusively present 
in these neuronal microdomains (Ledesma et al., 2000).  
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Figure 8 Analyses of DRM-dependent plasminogen binding and plasmin activation. Plasmin activity (expressed 
in arbitrary units) was measured at the indicated times in membranes isolated from young wt, DHCR24+/- and 
DHCR24-/- mouse brains. (A) DHCR24 depletion led to decreased plasmin activity in mouse brains in a dose 
dependant manner. (B) Plasmin activity was significantly reduced with DHCR24 depletion after addition of 
exogenous plasminogen, pointing to a reduced ability of membranes to bind plasminogen in DHCR24 depleted 
mice. (C) Membrane bound plasminogen was significantly reduced in DHCR24+/- and was absent in knock-out 
brains. (D) Endogenous levels of cellular plasminogen were not altered in any of the groups. The graphs below 
show the mean values and standard errors from the densitometric quantification of the Western blots from two 
independent experiments. Data were normalized to the amount of membrane bound GAPDH (not shown) and are 
expressed as percentage of the values obtained in the wt mice (**p<0.006). 
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We measured plasmin enzymatic activity using the chromogenic substrate S-2251 specific for 
this protease. Plasmin activity in isolated membranes of DHCR24+/- brains was significantly 
reduced and an even more drastic decrease was observed in DHCR24-/- brains (Figure 8A). 
Additionally, to analyze plasminogen binding exogenous plasminogen was added to isolated 
membranes and plasmin activity was measured. Concurrently, DHCR24 depletion resulted in 
reduced plasmin activity indicating a diminished ability of these membranes to bind 
plasminogen (Figure 8B). Accordingly, the amount of endogenous plasminogen bound to the 
membrane was clearly reduced in DHCR24+/- brains (42.9±10.9% p=0.005) and undetectable 
in DHCR24-/- brains (Figure 8C), while the endogenous levels of total plasminogen were 
similar in all mouse brains (Figure 8D). 
 
3.2.5 BACE1-APP membrane compartmentalization, APP processing and Aβ generation  
APP metabolism is a membrane-related process, since the substrate APP and its cleaving 
enzymes are transmembrane proteins, influenced by membrane composition and organization. 
Several studies examining the effects of cholesterol depletion on APP processing demonstrate 
a strong link between membrane cholesterol concentrations and the production of Aβ.  Recent 
studies indicate that amyloidogenic processing seems to highly depend on how much 
cholesterol is extracted from cellular membranes: while a moderate reduction of cholesterol 
resulted in increased Aβ production in primary neurons (Abad-Rodriguez et al., 2004), 
extensive cholesterol depletion resulted in significantly reduced Aβ levels in cellular models 
(Ehehalt et al., 2003; Kojro et al., 2001; Parvathy et al., 2004; Simons et al., 1998). In these 
studies, cholesterol lowering drugs and/or cholesterol extracting agents were used to reduce 
cellular and membrane cholesterol concentrations. To study the effects of cholesterol 
reduction on BACE and APP membrane segregation and their functional interaction in vivo, 
we analyzed DHCR24+/- mice exhibiting a moderate cholesterol depletion of approximately 
25% and DHCR24-/- mice as a model for a chronic cholesterol deficiency. While in wt brains 
36.4±3.6% of BACE was present in DRM fractions 4-6, this portion was significantly reduced 
(9.7±1.9%, p=0.025) in DHCR24+/- brains. In DHCR24-/- brains BACE was completely 
shifted to APP containing soluble fractions (Figure 9A). Endogenous APP is known to reside 
mainly outside rafts and remained in the soluble fractions 8-10 to a similar extent in all three 
genotypes (Figure 9B). Levels of cellular full-length APP were similar in all three groups, and 
there was no significant alteration in membrane bound fractions of full-length APP (Figure 9C 
and E). To test if the changes in membrane compartmentalization had a functional 
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consequence on APP processing we measured the levels of CTFs in brains of these mice 
(Figure 9C-F). While the amount of α-CTF was not significantly changed between the 
genotype groups, the β-CTF was markedly increased in DHCR24+/- brains (201±16%, 
p=0.021, Figure 9C and D) but significantly reduced in DHCR24-/- brains (54±5.6%, p=0.009) 
when compared to wt mice (Figure 9E and F). To determine to which extent these changes in 
APP processing and membrane compartmentalization affect Aβ generation, we determined 
the concentration of murine Aβ by specific ELISA (Fukumoto et al., 2002) (Figure 9G). Aβ40 
levels were significantly increased in DHCR24+/- brains (152±16%, p=0.027) but markedly 
decreased in brains of DHCR24-/- mice (42.9±4.3%, p=0.021). Since endogenous Aβ42 levels 
in young mice are extremely low (Refolo et al., 2001), Aβ42 was below detection level in 
brains of all three genotypes (Figure 9G).  
In conclusion, these data provide evidence that APP processing and Aβ generation are 
strongly influenced by DHCR24 disruption in a cholesterol-dependent manner in vivo. It was 
previously shown that the proteolytic activity of the β-secretase is lipid dependent and directly 
influenced by membrane cholesterol concentrations (Kalvodova et al., 2005) and γ-secretase 
activity was shown to be modulated by cellular cholesterol levels (Burns and Duff, 2002; 
Runz et al., 2002; Wahrle et al., 2002). 
 
 
 
 
 
 
 
 
Figure 9 BACE-APP membrane compartmentalization and APP processing in DHCR24 depleted mice. (A) 
BACE1 distribution along the sucrose gradient fractions was significantly altered with DHCR24 depletion, while 
flotation profiles of APP (B) did not reveal any differences between the genotypes. Left pictures show 
representative examples. Graphs on the right indicate the amount of BACE1 and APP in each fraction as a 
percentage of total BACE1 and APP, respectively. APP β-cleavage was analyzed by Western blot of cellular 
extracts containing equal amount of protein prepared from wt and DHCR24+/- (C), and wt and DHCR24-/- (E) 
brains. APP CTFs were normalized to the amount of full length APP and the percentages in wt mice were 
considered as 100%. Levels of α-CTF were similar in all three genotypes (C-F). DHCR24+/- mice revealed a 
significant increase in β-cleavage (D), while β-CTF in brains of DHCR24-/- mice was significantly reduced (F). 
Murine Aβ ELISA measurements showed an increase of Aβ40 in DHCR24+/- brains, while this peptide was 
significantly decreased in knock-out brains. Aβ42 peptides were below detection level in brains of all three 
genotypes (G). Proteolytic activity of APP cleaving secretases was unchanged in DHCR24+/- brains, whereas β- 
and γ-secretase were significantly decreased in knock-out brains (H) (*p<0.04, **p<0.01). 
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Therefore, to evaluate whether the changes in APP processing and Aβ generation were due to 
altered activities of involved secretases, we determined α-, β- and γ-secretase activity in brain 
homogenates of DHCR24 depleted and wt mice (Figure 9H). Brain activity levels of all three 
secretases were unchanged in DHCR24+/- mice, whereas a significant reduction of β-secretase 
activity (71.4±2.4%, p=0.025) and a moderate but still significant decrease in γ-secretase 
activity (90.2±5%, p=0.039) was found in DHCR24-/- mouse brains, which is likely to 
contribute to the observed changes in Aβ production in DHCR24-/- brains. These data suggest 
that the observed increase in amyloidogenic processing of APP in DHCR24+/- brains is most 
probably due to the changes in BACE and APP distribution throughout membrane 
compartments, rather than a consequence of altered secretase activity. However, impaired β- 
and γ-secretase activity in DHCR24-/- mice suggests that the membrane composition present 
in brains of these mice is not optimal to ensure full secretase activity.  
Our data of the young DHCR24-/- mice analyses are in agreement with the observation of 
reduced amyloidogenic APP cleavage in situations of drastic cholesterol depletion (Ehehalt et 
al., 2003; Simons et al., 1998). Moreover, we could confirm the in vitro data published by 
Abad-Rodriguez et al. suggesting that a moderate cholesterol reduction leads to disturbances 
in DRM formation and increased amyloidogenic processing of APP in our DHCR24+/- mouse 
model in vivo. We therefore conclude that proper raft organization is necessary to maintain a 
certain steady state level of Aβ. 
 
3.2.6 Protein abundance and phosphorylation  
Lipid rafts sequester signaling proteins of many kinds, including heterotrimeric G protein 
subunits, receptor tyrosine kinases, and Src-like kinases. Although their biological function is 
still poorly understood, rafts have been shown to act as membrane platforms for regulating 
signal transduction in many cell types (Simons and Toomre, 2000). In a preliminary 
experiment, we analyzed phosphorylation of the main mitogen-activated protein kinases 
(MAPKs) in wt and DHCR24 depleted mice to determine pathways that are possibly altered 
with moderate cholesterol shortage, as modeled in DHCR24+/- mice, and chronic cholesterol 
deficiency as determined in DHCR24-/- mice. The stress activated protein kinases (SAPKs) 
and p38 kinases constitute together with extracellular signal-regulated kinases (ERKs) the 
family of MAPKs. It was shown that the phosphorylation status of many MAPKs is 
influenced by the subcellular distribution and concentration of cholesterol (Ballard-Croft et 
al., 2006; Dobreva et al., 2005) and altered signaling events were described in mouse models 
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with enzyme defects in cholesterol biosynthesis and impaired cholesterol transport such as 
Niemann Pick disease (NPD) (Cooper et al., 2003; Sawamura et al., 2003; Sawamura et al., 
2001).  
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Figure 10 Protein phosphorylation and abundance in brains of DHCR24 depleted mice. Western blot analyses of 
signaling cascades involving ERK and SAPK (A) and GSK and TAU (B) did not reveal any difference in 
phosphorylation of these proteins between the three genotypes. (C) The phosphorylation of both phospho-sites of 
PKB/Akt (Ser473 and Thr308) was significantly increased in DHCR24-/- brains, whereas no difference was 
detected between DHCR24+/- and wt brains. p38 phosphorylation was significantly reduced in DHCR24+/- and 
knock-out mice and the levels of membrane associated RhoA were markedly diminished in knock-out brains 
(*p<0.021). 
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Moreover, we determined phosphorylation and protein concentration of a variety of proteins 
known to be involved in signaling cascades affected by cholesterol depletion such as 
Glycogen Synthase Kinase 3β (GSK) and Tau (Yu et al., 2005), Protein Kinase B (Akt/PKB) 
(Porstmann et al., 2005), and membrane associated Rho GTPase A (Pedrini et al., 2005). 
Phosphorylation of Erk and SAPK was similar in all three genotypes (Figure 10A) and 
additionally, phosphorylated GSK and S202 phosphorylated Tau did not reveal any 
differences between the genotypes (Figure 10B). However, PKB/Akt phosphorylation at both 
activation sites (Ser473 and Thr308) was significantly increased in DHCR24-/- brains 
(176±21%, p=0.041 and 199±25%, p=0.019, respectively, Figure 10C). In contrast, p38 
phosphorylation was markedly reduced in brains of DHCR24+/- and DHCR24-/- mice 
(39±9.1%, p=0.012 and 29.5±8.2%, p=0.012, respectively, Figure 10C) and membrane 
associated RhoA was also significantly decreased in DHCR24-/- brains (28.1±8.1%, p=0.021, 
Figure 10C). These findings suggest that cholesterol paucity may influence certain cell 
signaling events while others remain unaffected.  
 
 
3.3 MODELED DESMOSTEROL INCREASE IN SH-SY5Y CELLS 
To determine whether the decrease in cholesterol and not the increase in desmosterol levels is 
responsible for the observed changes in DHCR24+/- mouse brains, we artificially increased 
the levels of desmosterol in SH-SY5Y neuroblastoma cells, while cellular cholesterol levels 
were not altered, and determined DRM formation, plasmin activity and APP β-cleavage in 
these cells. Methyl-β-cyclodextrin is a cyclic oligosaccharide, consisting of seven 
glucopyranose units, which was demonstrated to efficiently remove cholesterol from a variety 
of cells in culture. Hydrophobic guest molecules, such as cholesterol or other sterols can be 
incorporated into the cavity of cyclodextrin by displacing water. The resulting complex is 
water-soluble, although the guest molecule can be easily released. Methyl-β-cyclodextrin can 
also be used for the reverse purpose: coupling of the oligosaccharide with a guest molecule 
allows its addition to encountering cellular membranes. The capacity of membranes to 
incorporate additional sterols is limited and depends on the nature of the integrating molecule. 
We incubated desmosterol/methyl-β-cyclodextrin inclusion complexes for 1 hour (desmo) 
with SH-SY5Y cells. TLC analysis revealed that this treatment induced an average six-fold 
increase in the amount of desmosterol compared to untreated control (contr) cells (Figure 
11A). 
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Ceramide levels, shown as a loading control, were not significantly changed between the two 
groups. To also model cholesterol deficiency in SH-SY5Y cells, we treated cells with the 
statin mevilonin and methyl-β-cyclodextrin to reduce about 30% of cellular cholesterol 
(mev/CD).  
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Figure 11 Methyl-β-cyclodextrin mediated desmosterol increase and cholesterol extraction from SH-SY5Y 
cells. SH-SY5Y cells were treated with desmosterol/Methyl-β-cyclodextrin compexes (desmo) or Methyl-β-
cyclodextrin alone (mev/CD) and compared to untreated cells (control). (A) Increased desmosterol levels were 
verified by TLC. Ceramide levels, shown as a loading control, were not significantly changed. The graph on the 
right shows the mean values and standard error from the densitometric analysis of the TLCs from two 
independent experiments. Desmosterol content is given as the fold-increase in treated with respect to the 
corresponding level of the untreated cells. (B) Flotation profiles revealed that reduced cholesterol concentrations, 
but not increased desmosterol levels resulted in displacement of the DRM marker protein from the DRM 
fractions. (C) Activity assays showed that plasmin activity of cellular membranes is reduced with cholesterol 
reduction but not in cells with higher desmosterol levels. (D) Western blot analyses revealed an increase in β-
CTF in cholesterol depleted cells, while desmosterol increase did not affect APP processing. The graph on the 
right shows the mean values and standard errors from the densitometric quantification of the Western blots from 
two independent experiments. Data were normalized to the amount of APP and are expressed as percentage of 
the values obtained in the untreated cells. 
 
The flotation profile of the raft marker flotillin-1 revealed that reduced cholesterol level, but 
not increased desmosterol levels resulted in displacement of the raft marker protein from 
DRM fractions (Figure 11B). Plasmin activity expressed in arbitrary units measured in freshly 
prepared membranes of SH-SY5Y cells treated as described above revealed that cholesterol 
reduction, but not higher desmosterol levels in the DRMs, reduced the plasmin activity of 
cellular membranes (Figure 11C). Western blot analyses using the 6E10 antibody that 
specifically recognizes full length APP and its β-CTF revealed not significant changes 
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between desmosterol/methyl-β-cyclodextrin complex and control cells, whereas β-CTF levels 
were significantly increased in mevilonin/cyclodextrin treated cells (135±7%, p=0.021) that 
exhibited a moderate cholesterol reduction, a situation comparable to that in young 
DHCR24+/- mice (Figure 11D). These data clearly show that moderately reduced cholesterol 
resulted in increased β-cleavage of APP in SH-SY5Y cells, whereas an average six-fold 
increase in the amount of desmosterol does not affect DRM formation, plasmin activity and 
APP processing. Efforts to model the membrane sterol constitution of DHCR24-/- mice in SH-
SY5Y cells were unsuccessful. The inhibition of cholesterol biosynthesis by statin treatment 
and the complete removal of cholesterol using methyl-β-cyclodextrin before replenishing 
membranes with desmosterol is a harsh method, apparently delimitating cell viability.  
 
 
3.4 APP PROCESSING IN PRIMARY NEURONS OF DHCR24 DEPLETED MICE 
To examine the effects of DHCR24 depletion on APP ectodomain shedding and Aβ 
generation in vitro, without perturbing cell viability with numerous treatments, we prepared 
primary cortical neurons of wt and DHCR24 depleted mice in serum- and cholesterol-free 
medium complemented with B27. Immunocytochemistry using the neuron specific antibody 
anti-Map2 revealed no obvious differences in morphological appearance between wt, 
DHCR24+/- and DHCR24-/- neurons (Figure 12A). Additionally, there were no differences in 
cell viability between the neuronal cultures as determined by the in vitro toxicology assays 
based on Lactate-Dehydrogenase (LDH) and on Tox-1 (MTT) (Figure 12B). Sterol analysis 
revealed that the total level of sterols was significantly reduced in primary neurons of 
DHCR24-/- mice (56±5.6%, p=0.021), whereas in neurons of DHCR24+/- mice the levels were 
unchanged compared to wt neurons after 5 days in vitro (Figure 12C). Because DHCR24-/- 
neurons are devoid of cholesterol, these data suggest that, like in young mouse brains, 
desmosterol accumulated as a consequence of DHCR24 deficiency in primary neurons. The 
finding that sterol levels were not altered in DHCR24+/- neurons might be due to a generally 
reduced cholesterol biosynthesis in primary neurons in vitro when compared to young 
animals. A reduced rate of synthesis would result in full cholesterol production, because the 
amount of DHCR24 in heterozygous mice is sufficient to completely convert accruing 
substrates. Analysis of the medium from neuronal cultures revealed that the level of sAPPα in 
supernatants of DHCR24+/- neurons was unchanged, but markedly increased in DHCR24-/- 
neurons compared to control cultures (143±12.5%, p=0.023, Figure 12D). 
Results 59
0
20
40
60
80
100
120
140
%
 o
f w
t n
eu
ro
ns
%
 o
f w
t n
eu
ro
ns
%
 o
f w
t n
eu
ro
ns
%
 o
f w
t n
eu
ro
ns
MTT LDH total sterols
secreted sAPPα
secreted
Aβ40
secreted
Aβ42
+/+ -/-
primary neurons
sAPPα
β-actin
medium
cell lysate
cell lysate
FL  APP
+/-
+/+
+/-
-/-
+/+
+/-
-/-
+/+
+/-
-/-
+/+
+/-
-/-
0
20
40
60
80
100
120
0
20
40
60
80
100
120
140
160
0
20
40
60
80
100
120
10X
20X
+/+ +/- -/-A
B C
D
E
*
*
****
 
Figure 12 APP processing in primary neurons of DHCR24 depleted mice. Anti-Map2 staining (A) and cell 
viability assays (B) of primary neurons of each genotype did not reveal any significant differences between the 
cultures. (C) Sterol measurements show that DHCR24-/- neurons contained significantly less amounts of total 
sterols, whereas sterol levels in DHCR24+/- neurons were similar to that in wt neurons. (D) Secreted sAPPα 
levels were increased in the medium of DHCR24-/- neurons, while no significant changes were detected between 
DHCR24+/- and wt cultures. The graph on the right shows the mean values and standard error from the 
densitometric analysis of the Western blots from two independent experiments. (E) ELISA measurements of the 
medium revealed no difference in Aβ levels between DHCR24+/- and wt cultures, but a significant decrease of 
Aβ40 and Aβ42 in the medium of DHCR24-/- neurons. Data were normalized to the amount of proteins in the 
respective cultures and are expressed as percentage of the values obtained from wt cultures (*p<0.03, 
**p<0.002). 
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The level of full length APP in cell homogenates was similar in all three genotypes (Figure 
12D). Measurements of Aβ40 and Aβ42 peptides in the medium of the neuronal cultures by 
murine Aβ ELISA revealed no differences between wt and DHCR24+/- neurons, while these 
peptides were significantly reduced in supernatants of DHCR24-/- neurons (58.7±21.1%, 
p=0.001 and 57.4±15.9%, p=0.001, respectively, Figure 12E). These results show that 
extensive cholesterol deficiency in DHCR24-/- neurons resulted in increased α-secretase type 
ectodomain shedding and decreased Aβ generation. 
 
 
3.5 ADULT DHCR24 DEPLETED MICE 
Taking the central role of cholesterol in development, in cell viability and various cell 
functions and in membrane organization, the question arises why cholesterol-free DHCR24-/- 
mice show such a mild phenotype. One possible explanation is the fact that maternal 
cholesterol is able to traverse the murine placenta and is therefore available during mouse 
embryogenesis. Although cholesterol accounts for over 99% of all sterols in wt brains, 
DHCR24-/- mice showed only a partial reduction of total sterol levels in the brain due to 
desmosterol accumulation. The nature of the accumulating sterol might be a second important 
factor determining the biophysical properties and functionality of membranes containing the 
substitutional sterol. On the one hand, our data clearly show that in brains of young DHCR24-
/- mice, membrane organization and function is significantly disturbed, resulting in deficient 
DRM formation and altered membrane-related functions such as APP processing. On the 
other hand, cell viability and several signaling cascades are not affected in these mice, 
suggesting at least a partial replacement of cholesterol by desmosterol. The finding that 
desmosterol is greatly accumulating in young DHCR24-/- mice without getting efficiently 
catabolized rises the question, if desmosterol concentrations increase to even higher levels in 
adult knock-out brains and, if so, whether desmosterol is capable of efficiently substituting 
cholesterol in the adult brain. We therefore analyzed adult wt, DHCR24+/- and DHCR24-/- 
mice at the age of 16 weeks. This time point was chosen to ensure a good state of health of 
DHCR24-/- mice. 
 
3.5.1 Sterol concentrations and gene expression analysis  
Brain sterol concentrations were determined in adult wt, DHCR24+/- and DHCR24-/- mice by 
gas-chromatography/mass-spectrometry (Figure 13A and Table 4). Lanosterol levels were 
unchanged in DHCR24+/-, but significantly reduced in DHCR24-/- mice (72.6±2.9%, p=0.021). 
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Table 4 Brain concentrations (ng/mg wet weight; mean ±SD) of cholesterol, desmosterol, lanosterol, lathosterol 
and 24S-OH-cholesterol of adult (16 week-old) wildtype, DHCR24+/- and DHCR24-/- mice 
      
Genotype Lanosterol Desmosterol Lathosterol Cholesterol 24S-OH-Chol 
      
wt 27±3       463±24 140±14 75,240±2,118 157±7 
DHCR24+/- 23±2    1,263±122*   96±9* 77,115±3,255 148±5 
DHCR24-/- 19±2* 96,751±10,956*     1±0.4*   3,065±319*   10±2* 
      
*p<0.03 vs. aged-matched controls. Exact p-values are given in the text 
 
Desmosterol accumulation in adult DHCR24+/- mice (463±23%, p=0.021) was comparable to 
that in young DHCR24+/- mice (see Figure 5A), while adult DHCR24-/- mice revealed an even 
greater build-up of desmosterol (21743±1182% of wt, p=0.021, Figure 13A). Quantitatively, 
the brain concentration of desmosterol in 16 week-old DHCR24-/- mice was comparable to the 
concentration of cholesterol in aged-matched wt mice (Figure 13B and Table 4). Lathosterol 
was significantly reduced in adult DHCR24+/- mice (68.6±3.6%, p=0.021), whereas the levels 
of cholesterol and its catabolite 24S-OH-cholesterol were unchanged between adult wt and 
heterozygous mice. These results suggest that the reduced levels of DHCR24 in heterozygous 
mice are necessarily capable of maintaining cholesterol homeostasis in adult DHCR24+/- mice, 
particularly since cholesterol biosynthesis is drastically reduced during postnatal 
development. This finding is in concert with data obtained from heterozygous desmosterolosis 
patients who show mildly increased levels of desmosterol in tissue and plasma but normal 
levels of cholesterol (Andersson et al., 2002). In adult DHCR24-/- brains lathosterol, 
cholesterol and 24S-OH-cholesterol were virtually absent (0.87±0.15%, 4.07±0.21% and 
6.39±0.64%, p<0.03, respectively, Figure 13A), corroborating the hypothesis that no other 
enzyme of the two pathways is able to take over the function of DHCR24. 
Expression analysis of cholesterol and fatty acid synthesis related genes revealed no 
significant differences between adult DHCR24+/- and wt brains (Figure 13C). Expression of 
dhcr24 was significantly reduced in DHCR24+/- brains (48.3±6.4%, p=0.021, Figure 13C), 
suggesting that dhcr24 expression is not influenced by chronic cholesterol paucity or 
desmosterol accumulation. Sterol analyses in adult DHCR24-/- brains revealed that the 
observed changes in fas expression in three week-old DHCR24-/- mouse brains were abolished 
in adult knock-out mice (Figure 13C), indicating that high concentrations of desmosterol 
might substitute the role of cholesterol in this feedback mechanism. Moreover, the detected 
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down-regulation of hmgcr in young DHCR24-/- brains was abolished in adult knock-out mice, 
which showed expression levels similar to those in wt mice (Figure 13C). Since lanosterol 
levels were also reduced in the adult knock-out mice, these data support the theory of a 
possible feedback mechanism from early Bloch-sterols or their derivatives on the 
transcriptional level of the rate-limiting enzyme HMGCR. 
0100200300 0 806020 40
Lathosterol
Desmosterol
Lanosterol
24S-OH-Chol
Cholesterol
rel. sterol abundance
(% of wildtype)
abs. sterol conc.
(µg/mg wet weight)
+/+
+/-
-/-
+/+
+/-
-/-
21743
0
50
100
150
200
re
l. 
m
R
N
A
 le
ve
l
(%
 o
f w
t)
+/+
+/-
-/-
hmgcr srebp1 fassrebp2 dhcr24
A B
C
*
**
*
*
*
*
*
*
 
Figure 13 Brain sterol synthesis and elimination and gene expression analyses in adult DHCR24 depleted mice. 
(A) Lanosterol levels were unchanged in DHCR24+/- brains and a small but significant reduction was detected in 
DHCR24-/- brains. Desmosterol concentrations in adult DHCR24+/- mice were increased, while desmosterol 
tremendously accumulated in adult knock-out brains. Lathosterol levels were significantly reduced in DHCR24+/- 
brains and virtually absent in DHCR24-/- brains. Cholesterol concentrations and levels of 24S-OH-chol were not 
altered in DHCR24+/- brains but vastly diminished in knock-out brains. (B) In adult DHCR24+/- brains cholesterol 
levels were recovered when compared to aged-matched controls. Absolute desmosterol concentrations in 16 
week-old DHCR24-/- brains were similar to those of cholesterol concentrations in wt mice. (C) Changes in gene 
expression detected in young DHCR24 depleted mice were annulled in adult mice, except a significant up-
regulation of srebp1 in DHCR24-/- brains, which was similar to that seen in young knock-out mice. DHCR24 
expression was reduced in DHCR24+/- brains to the same extent as in young heterozygous mice and absent in 
adult DHCR24-/- brains. Data were normalized to the mean value of the two housekeeping genes gapdh and β-
actin. Relative mRNA levels of the respective genes in wt brains were considered as 100% (*p<0.03). 
 
In parallel to three week-old mice and in agreement with published results (Ohyama et al., 
2006) the srebp1 expression in adult DHCR24-/- brains was significantly higher than that in wt 
controls (176±6.5%, p=0.012, Figure 13C), suggesting that desmosterol accumulation did not 
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influence srebp1 expression in the brain, as already indicated by the results of the in vitro 
treatment of SH-SY5Y with sterols (Figure 5D). Having demonstrated that membrane 
organization and DRM formation is disturbed in brains of young DHCR24-/- mice (Figure 6 
and Figure 7), which show desmosterol levels accounting for approximately 50% of wt 
cholesterol levels, we next addressed the question if higher levels of desmosterol can 
functionally substitute cholesterol in brains of adult DHCR24-/- mice. Since heterozygous 
mice at the age of 16 weeks did not reveal any differences in brain cholesterol concentration 
compared to their wt littermates, we focused on adult knock-out and wt mice for further 
analyses. 
 
3.5.2 Membrane organization: DRM protein distribution and sterol repartition  
To evaluate if the observed increase in desmosterol concentration in adult DHCR24-/- mice 
has an effect on membrane organization we analyzed DRM formation and protein 
composition in adult DHCR24-/- brains. The total amount of protein in each fraction did not 
significantly differ between the two genotypes (Figure 14A). Analysis of the flotation profile 
of Prpc revealed the presence of comparable percentages (13.8±4.2% and 15.8±3.7%, 
respectively, Figure 14B) of this raft marker in DRM fractions of adult DHCR24-/- and wt 
brains. Compared to young knock-out mice, adult DHCR24-/- mice exhibited a drastic 
increment of Prpc in the DRM fractions, suggesting major differences in membrane 
organization of DHCR24-/- mice between the two age groups.  
The non-raft protein APP remained in the soluble fractions of the gradients to the same extent 
in brains of both genotypes (Figure 14C). Analysis of the total sterol levels in soluble and 
DRM fractions of the gradients revealed no significant changes of sterol levels in heavy 
fractions 8-10 of adult DHCR24-/- brains (Figure 14D). In marked contrast to three week-old 
mice (Figure 7A), a substantial amount of sterols was detected in DRM fractions of adult 
DHCR24-/- brains (83.2±6.2% of wt, Figure 14D), suggesting that desmosterol associated with 
DRM fractions of adult DHCR24-/- brains. The amount of phospholipids was unchanged 
between the two genotypes (Figure 14E). Taken together, these results show that in 
membranes entirely lacking cholesterol, high concentrations of desmosterol allow DRM 
formation and protein recruitment of raft marker in these domains. Furthermore, these 
observations suggest that desmosterol in adult DHCR24-/- mice principally resides in the same 
flotation fractions of brain extracts as cholesterol in wt controls. However, it remains to be 
determined if high desmosterol concentrations can functionally replace cholesterol in vivo. 
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Figure 14 Effects of desmosterol substitution of cholesterol on membrane protein distribution and lipid 
composition in adult DHCR24-/- brains. (A) Percentages of total protein in DRM fractions 4-6 were unchanged 
between adult knock-out and wt mice. Western blot analyses of flotation profiles of the raft marker Prpc (B) and 
the non-raft protein APP (C) revealed no significant differences in the distribution of the two proteins. Graphs on 
the right show the distribution of both proteins in each fraction as a percentage of the total amount of the 
respective proteins along the entire gradient. (D) Sterol analysis in soluble and DRM fractions of the gradient 
revealed a considerable amount of sterols present in DRM fractions of DHCR24-/- mice. Therefore, no significant 
difference were detected between adult DHCR24-/- and wt mouse brains. While cholesterol is assumed to 
represent most sterols in wt fractions, desmosterol accounts for the majority of sterols in knock-out fractions (see 
Table 4). (E) Phospholipid concentrations in total brain extracts are similar in adult mice of both genotypes. 
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3.5.3 Functional replacement of cholesterol by desmosterol  
Therefore, we determined if membrane-related functions such as APP processing and Aβ 
generation occur at normal levels in brains of these mice. Levels of cellular full-length APP 
were similar in both genotypes (Figure 15A). Additionally, analysis of APP processing 
products revealed no detectable changes in levels of α-CTF and β-CTF in adult DHCR24-/- 
mouse brains (Figure 15A and B) when compared to wt mice. To determine if Aβ generation 
is influenced by the presence of membrane desmosterol we performed murine Aβ ELISA. 
Measurements of total extracts containing soluble and membrane bound portions of Aβ 
peptides revealed no detectable changes in the concentration of Aβ40 between adult DHCR24-
/- and wt mice (Figure 15C), in contrast to reduced Aβ40 levels detected in young DHCR24-/- 
mice (Figure 9G). In 16 week-old mice Aβ42 peptides were also detectable in total extracts of 
both genotypes, which did not differ between adult knock-out and wt mice (Figure 15C). To 
evaluate whether the observed changes in proteolytic activity of involved secretases in young 
DHCR24-/- mice were abolished by desmosterol membrane repartition, we determined α-, β- 
and γ-secretase activity in brain homogenates of adult DHCR24-/- and wt mice (Figure 15D).  
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Figure 15 Functional replacement of cholesterol by desmosterol. (A) Representative Western blots show that 
cellular levels of full length (FL) APP and its cleavage products α- and β-CTF are unchanged between adult 
DHCR24-/- and wt mice. (B) The graph shows the mean values and standard error from the densitometric 
analysis of the Western blots. (C) Aβ40 and Aβ42 levels are similar in adult knock-out brains when compared to 
wt controls. (D) Full proteolytic activity of all three secretases involved in APP processing is ensured in brains of 
adult DHCR24-/- mice. 
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Brain activity levels of all three secretases were unchanged in adult DHCR24-/- compared to 
wt mice, suggesting that desmosterol influences membrane organization in a way that full β-
and γ-secretase activity is maintained. Moreover, quantitative analyses of phosphorylated 
proteins involved in signal transduction revealed that the observed changes in Akt and p38 
phosphorylation were abolished in adult DHCR24 depleted mice (Figure 16). 
In addition, membrane association of RhoA in adult DHCR24-/- mice was not altered 
compared to aged-matched control mice. These data provide the evidence that desmosterol - 
insofar it is abundant enough - can substitution cholesterol in biological membranes leading to 
its functional replacement in APP metabolism in vivo. Furthermore, the steady state 
phosphorylation status of signaling peptides known to be modulated by altered cholesterol 
concentrations is maintained in adult DHCR24 depleted mice, confirming the functional 
replacement of cholesterol by desmosterol. 
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Figure 16 Protein phorsphorylation and abundance in brains of adult DHCR24 depleted mice. Western blot 
analyses revealed no differences in the phosphorylation of both phospho-sites of Akt (Ser473 and Thr308) and 
p38 phosphorylation between the three genotypes. In addition, no difference was detected in membrane 
associated RhoA between wt, DHCR24+/- and DHCR24-/- brains. GAPDH on total brains homogenates and 
membrane preparations was stained as loading control. 
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4. DISCUSSION 
 
4.1 DHCR24 DEPLETED MICE 
The results presented in this thesis show that brain cholesterol levels can be modulated by 
modifying the expression of the cholesterol-synthesizing enzyme, DHCR24. Our approach is 
different from previous work that relied on pharmacological inhibition of early steps of 
cholesterol synthesis or on using lipid extracting drugs that has led to controversial results 
(Ehehalt et al., 2003; Fassbender et al., 2001; Simons et al., 1998; Sparks et al., 1994). We 
show that the depletion of one dhcr24 allele resulted in a moderate cholesterol reduction of 
about 25% in brains of DHCR24+/- mice, whereas complete dhcr24 disruption led to total 
cholesterol deficiency in DHCR24-/- brains. As a consequence, membrane organization and 
DRM composition and function were significantly altered in a cholesterol-dependent manner, 
revealing major changes in membrane-related functions such as plasmin activation, APP 
processing and Aβ generation.  
Considering that cholesterol is an essential component of vertebrate cell membranes and 
exhibits essential biological roles, it is striking that DHCR24 knock-out mice survive beyond 
birth. The question arises which mechanism/s enable the DHCR24-/- mice to reach embryonic 
maturation and postnatal development. With mice, in contrast to humans, cholesterol passes 
the placenta. Therefore, one reasonable answer is that circulating cholesterol, contributed 
from the heterozygous mother, suffices for early development. In this scenario, soon after 
birth DHCR24-/- mice are compromised due to the deficiency in synthesizing cholesterol and 
seriously depend on maternal care. Though cholesterol ingested with breast milk is kept from 
the brain through the BBB, it does supply the pup’s periphery, and most likely contributes to a 
normal postnatal development. Since the DHCR24 knock-outs are smaller in size and 
probably also exhibit other abnormal symptoms recognized by the mother, such as differences 
in hormones or dermatological attributes (Mirza et al., 2006), some pups were killed by the 
mother within hours of birth. In addition, many knock-out pups died within days after birth as 
a consequence of weakness to assert themselves against their healthy littermates in terms of 
feeding. Moreover, the reduced frequency of born knock-out mice indicates some prenatal 
death, although knock-out mice in our colony were born to an even higher frequency (15-
20%) as previously described (Wechsler et al., 2003). Neuronal preparation from embryos at 
E13-16 revealed a comparable frequency of knock-out embryos, indicating that prenatal death 
occurs earlier in embryonic development.  
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Embryonic development and the postnatal survival of the DHCR24 knock-out mice may also 
depend on the nature of the substituting sterol. This issue is discussed in detail in section 4.4. 
Once DHCR24-/- mice established themselves during the first weeks after birth, their 
surviving was warranted. Strikingly, neuropathological and biochemical analysis did not 
reveal any differences concerning morphology, viability or apoptotic and inflammatory events 
in brains of DHCR24-/- mice of different age-groups. We did not examine any peripheral 
parameters like serum components, hormone levels or bile acids and therefore we can not rule 
out potential differences, which possibly affect the general health status of knock-out mice.  
 
In brains of young DHCR24 depleted mice, cholesterol was reduced due to a gene dose-
dependent effect in DHCR24+/- brains, whereas in DHCR24-/- brains cholesterol was virtually 
absent. It was shown that cholesterol biosynthesis is high in the brain of newborn mammals 
but is reduced during postnatal development (Ohyama et al., 2006). This change in 
biosynthetic activity possibly explains why adult DHCR24+/- mice did not show any 
differences in cholesterol concentrations, as observed in young heterozygous mice. Since no 
up-regulation of dhcr24 expression was detected in adult DHCR24+/- mice, we conclude that 
dhcr24 expression is not directly regulated by cholesterol levels. Another mechanism that 
could contribute to the gain-back of cholesterol in adult heterozygous mice is a reduced 
catabolism of cholesterol by diminished conversion to 24S-OH-cholesterol. Early sterols of 
the Bloch-pathway such as lanosterol accumulated in young DHCR24-/- brains, while this 
accumulation was not observed in adult knock-out mice. In contrast, lanosterol levels in adult 
DHCR24-/- brains were significantly reduced, implying a generally decreased activity of 
cholesterol biosynthesis in these mice, possibly mediated by tremendously increasing 
desmosterol levels. Since desmosterol is the last sterol of the Bloch-pathway and is solely 
converted by DHCR24, it gradually accumulated in spite of reduced biosynthetic activity. 
Given that desmosterol concentrations in adult DHCR24-/- mice are even overtopping 
cholesterol concentration in aged-matched wt controls, we have to assume that other possible 
feedback mechanism are set off, maybe similar to those caused by high cholesterol levels. 
One indication for this hypothesis is the normalized regulation of fas expression in adult 
knock-out mice compared to controls, while in young knock-out mice a clear up-regulation 
was detected, when compared to wt controls. Analyses of sterol distribution and expression of 
cholesterol and fatty acid biosynthesis related genes also suggest possible other feedback 
mechanisms: The accumulation of lanosterol in young DHCR24-/- mouse brains seems to 
influence transcription of hmgcr, the rate-limiting enzyme in cholesterol biosynthesis. 
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Previous studies showed that oxylanosterol, an oxygenated derivative of lanosterol, is 
involved in regulation of HMGCR-activity and cholesterol biosynthesis (Panini et al., 1992; 
Panini et al., 1986). Moreover, lanosterol was shown to play a major role in post-
transcriptional regulation of HMGCR, by stimulating its degradation (Song et al., 2005). The 
finding that hmgcr expression is not altered in adult DHCR24-/- mice, which do not 
accumulate lanosterol and treatment of SH-SY5Y cells with lanosterol further revealed 
evidence for the hypothesis of a possible feedback mechanism of lanosterol on hmgcr 
expression. However, treatment of SH-SY5Y cells with high levels of desmosterol did not 
influence gene-expression, suggesting that the observed changes in gene expression in knock-
out mouse brains were most probably due to the paucity of cholesterol, rather than to the 
accumulation of desmosterol.  
 
4.2 MODERATE CHOLESTEROL REDUCTION IN DHCR24+/- MICE 
In a recent study, a moderate reduction of cholesterol through methyl-β-cyclodextrin mediated 
extraction from primary neurons resulted in disorganized DRMs, leading to increased 
amyloidogenic processing and elevated Aβ generation in these cells (Abad-Rodriguez et al., 
2004). It was hypothesized that the disruption of rafts through cholesterol depletion might 
lessen the sequestration of γ-secretase and BACE into rafts and result in a higher proportion of 
these secretases in the APP containing fractions of the membrane, therefore cleaving APP 
more frequently (Kaether and Haass, 2004). In our DHCR24+/- mice that bring out a good 
model for in vivo cholesterol reduction of about 30%, we could reproduce the findings from 
Abad-Rodriguez and colleagues, corroborating the belief that DRMs play a major role in the 
segregation process of APP from BACE, suggesting that proper DRM organization are 
essential to maintain the steady-state levels of Aβ.  
The finding that low expression of DHCR24 paralleled a reduction in brain membrane 
cholesterol offers a new perspective on the role that DHCR24 in might play in AD pathology. 
Because DHCR24 was shown to be down-regulated in vulnerable areas of brains in AD 
patients (Greeve et al., 2000) it is reasonable to think that lower levels of DHCR24, promoted 
by yet to be identified causes, are responsible for the membrane cholesterol reduction and 
disorganization of DRMs found in such brains (Ledesma et al., 2003a). This would 
consequently lead to Aβ accumulation via a combination of inefficient Aβ degradation, 
possibly due to low plasmin activity, and increased APP amyloidogenic cleavage. Iivonen et 
al., in contrast, could not find an association between reduced DHCR24 transcription levels in 
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AD brains and Aβ content (Iivonen et al., 2002). The fact that cholesterol levels were not 
measured in this study together with the low number of samples analyzed precludes drawing a 
definitive conclusion. Indeed, cholesterol loss has been observed in a significant number but 
not in all AD brains (Ledesma et al., 2003a). Altogether these data suggest that compensatory 
mechanisms to the effects of DHCR24 deficiency on cholesterol levels might exist that would 
differ among AD patients. Moreover, alternative mechanisms (i.e. mutations in APP or 
presenilins) might be responsible for Aβ  accumulation in certain AD cases. Further research, 
including large scale studies, is required to clarify these matters. 
 
4.3 CHRONIC CHOLESTEROL DEFICIENCY IN YOUNG DHCR24-/- MICE 
Our in vivo approach analyzing the brains of DHCR24-/- mice substantiates previous findings, 
that depletion of cholesterol by a degree greater than 30% resulted in elevated levels of 
sAPPα, reduced β-cleavage and diminished Aβ generation (Ehehalt et al., 2003; Kojro et al., 
2001; Parvathy et al., 2004; Refolo et al., 2001; Simons et al., 1998). However, in these 
studies, cholesterol lowering drugs or cholesterol extracting agents were used to reduce 
cellular and membrane cholesterol levels. We could show that chronic cholesterol deficiency 
in young DHCR24-/- brains leads to decreased amyloidogenic processing, resulting in reduced 
Aβ production. In addition to the deficient formation of DRMs in brains of young DHCR24-/- 
mice the proteolytic activity of BACE and the γ-secretase complex were significantly reduced, 
suggesting that the membrane composition in brains of these mice was suboptimal to maintain 
full enzymatic activity of the two secretases. This is in concert with several previous findings 
that disrupting cholesterol transport can alter presenilin distribution within the cell and affect 
APP processing (Burns et al., 2003; Runz et al., 2002), and depletion of membrane cholesterol 
resulted in complete inhibition of γ-secretase cleavage of APP (Wahrle et al., 2002). 
Moreover, it was shown that alterations in β-secretase activity might be responsible for the 
dependence of Aβ production on cholesterol levels. Cross linking experiments of APP and 
BACE in raft domains (Ehehalt et al., 2003) and targeting BACE exclusively to rafts (Cordy 
et al., 2003) remarkably affect Aβ production in a cholesterol-dependent manner. 
Furthermore, BACE activity in large unilamellar vesicles was shown to be directly influenced 
by membrane cholesterol concentrations (Kalvodova et al., 2005).  
 
Primary neurons of DHCR24-/- mice revealed decreased levels of total sterols after 5 days in 
culture, and the effects of this reduction on APP processing were similar to those detected in 
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young DHCR24-/- mice. Unfortunately, we were not able to reproducibly culture these 
neurons for the time period needed to increase desmosterol concentrations to considerably 
higher levels. However, in single experiments analyzed neurons cultured for 2 and for 8 days, 
revealed gradually increasing sterol levels (data not shown), indicating that desmosterol 
concentrations rise over time, just as it was observed in knock-out mice. Viability and 
endurance of primary neurons sensitively depend on general conditions like medium-
supplements, temperature, age of embryos for preparation, coating conditions of plates, etc. 
Therefore, we consider it possible to generally culture primary neurons of DHCR24-/- mice 
and wt controls for a longer period in vitro and suggest this for future experiments. Granted 
that desmosterol levels in aged primary neurons of DHCR24-/- mice reach such high levels as 
cholesterol in wt neurons or even higher, one could nicely show the correlation between 
cholesterol paucity, desmosterol increase and Aβ production. Furthermore, this cellular model 
would serve as an excellent system to analyze other effects of desmosterol on membrane 
organization and function, such as signaling, endocytic activity and also biophysical 
properties such as curvature and lipid packing. 
 
In a first screen of protein phosphorylation in brains of DHCR24 depleted mice, we 
determined an altered phosphorylation status of PKB/Akt and the stress kinase p38, and 
differences in the proportion of membrane bound RhoA in brains of young knock-out mice. 
Surprisingly, phosphorylation and protein abundance of other MAPK and of many other 
proteins were not altered in young DHCR24 depleted mice, suggesting cholesterol 
independent mechanisms. 
Porstmann et al. could recently show that PKB/Akt activation is necessary to induce 
transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of 
SREBP (Porstmann et al., 2005). Since we found respective genes differentially expressed in 
young DHCR24-/- mice, we analyzed PKB/Akt phosphorylation to determine possible 
regulatory mechanisms, and determined a hyperphosphorylation of Akt at both phospho-
epitopes in young DHCR24-/- brains. Moreover, these findings are in concert with data 
observed from aged primary neurons. Aging of wt neurons in culture led to a reduction of 
cholesterol concentration in these cells and this decrease was accompanied by a 
hyperphosphorylation of PKB/Akt due changes in DRM protein composition (Prof. Carlos 
Dotti, personal communication). PKB/Akt activation triggers a surviving cascade, possibly 
responsible for the long endurance of aging neurons in vitro and there are several explanations 
how cholesterol-dependent alterations in DRM composition could influence PKB/Akt 
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phosphorylation. In its inactive state, Akt is located in the cytosol; however, when the 
phosphoinositide phosphate, phosphoinoside 3,4,5-trisphosphate, is activated by 
phosphoinositide 3-kinase (PI3K) it recruits Akt and 3-phosphoinositide-dependent protein 
kinase 1 (PDK1) to the lipid bilayer. There, Akt is activated via phosphorylation on two 
residues, Thr308 and Ser473 (Alessi et al., 1996). Recruitment of proteins into lipid rafts and 
their phosphorylation/activation within rafts has previously been described for many different 
proteins, including PKB/Akt (Remacle-Bonnet et al., 2005) and the insulin receptor (Ikonen 
and Vainio, 2005; Vainio et al., 2005). One other possible mechanism is the subcellular 
dislocation of components in or out of lipid rafts that are responsible for Akt-activation such 
as the Trk receptor (Rajagopal et al., 2004). 
The finding that the stress kinase p38 is hypophosphorylated in brains of DHCR24 depleted 
mice is in line with previous findings that cholesterol is the major component of native 
lipoproteins activating the p38 mitogen-activated protein kinases (Dobreva et al., 2005).  
However, some changes determined in DHCR24-/- brains might not directly be associated 
with DRM composition. The finding that the membrane bound portions of RhoA were 
reduced in young DHCR24-/- mouse brains may be possible effects of the determined down-
regulation of hmgcr in brains of these mice. One popular hypothesis for statin action is related 
to the drugs’ inhibition of the isoprenoid pathway by inhibiting HMGCR, thereby modulating 
the activities of the Rho family of small GTPases - RhoA, B, and C - that need isoprenoid 
compounds for membrane coupling and activity. Rho proteins exert many of their effects via 
Rho-associated protein kinase (ROCKs) and a dominant negative form of ROCK was shown 
to increase sAPPα shedding, suggesting that altered APP processing induced by statin 
treatment is a consequence of changes in the Rho-ROCK protein phosphorylation pathway. 
The detected decrease in membrane associated RhoA therefore possibly contributes to the 
observed changes in APP processing and Aβ generation in DHCR24-/- mice. 
 
4.4 REPLACEMENT OF CHOLESTEROL BY DESMOSTEROL IN ADULT 
DHCR24-/- MICE 
In contrast to many relatives of cholesterol, desmosterol is an abundant structural membrane 
component in mammalian cells, such as spermatozoa and astrocytes (Lin et al., 1993; Mutka 
et al., 2004). Reduced ability to convert desmosterol to cholesterol leads to the human disorder 
desmosterolosis (as described in paragraph 1.2.5). This rare malformation syndrome is 
characterized by severe developmental defects and cognitive impairment (Andersson et al., 
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2002; FitzPatrick et al., 1998; Herman, 2003; Waterham et al., 2001). Instead, DHCR24 
knock-out mice that accumulate high amounts of desmosterol over time, exhibit an 
unexpectedly mild phenotype, being small and infertile but viable (see paragraph 1.2.6). This 
raises the question in how far desmosterol can be a substitute for cholesterol concerning 
membrane organization, DRM formation and membrane-related functions.  
Taking the central role of cholesterol in membrane composition and function, a variety of 
other sterols were analyzed towards their biophysical behavior in model membranes. Some of 
them were found to be “membrane-active sterols”, defined as sterols that decrease the 
membrane permeability, increase the order in the lipid acyl chains near the terminal methyl 
group, and enable the growth of sterol auxotroph microorganisms (Barenholz, 2002; Stottrup 
and Keller, 2006). For example, lathosterol, a distant precursor of cholesterol also lacking the 
C24 double bond, was shown to associate with rafts of cellular membranes at least as 
efficiently as cholesterol (Lusa et al., 2003; Wang et al., 2004). The effect of desmosterol on 
membrane lipid order, phase separation and lipid packing was found to be similar to that of 
cholesterol in model membranes, while significantly lower ordering effects of lanosterol were 
observed, a more distant precursor of cholesterol in the Bloch-pathway (Huster et al., 2005).  
Our analyses of adult DHCR24-/- mice suggest that desmosterol is capable in substituting 
cholesterol in biological membranes leading to its functional replacement in APP metabolism 
in vivo. We could show that the observed changes in membrane composition and DRM 
structure in brains of young DHCR24-/- mice, affecting secretase activity, β-cleavage of APP 
and Aβ generation, were annulled in adult knock-out mice. Therefore, we conclude that age-
related desmosterol accumulation and integration in membranes of adult DHCR24-/- mice is 
responsible for a normal distribution of membrane constituents, DRM formation and sustained 
APP metabolism.  
However, in model membranes desmosterol was shown to promote the formation and stability 
of ordered domains somewhat less efficiently than cholesterol (Vainio et al., 2006).  
Moreover, Vainio et al. found that in mammalian cell membranes desmosterol associated less 
avidly with DRMs than cholesterol. Their model is different from ours in that they use CHO 
cells containing high amounts of endogenous desmosterol concentrations, but normal levels of 
cholesterol, therefore they can not rule out that the presence of cholesterol affects 
desmosterol-DRM association. Despite this difference, our results are consistent with their 
findings that desmosterol is capable to associate with DRMs, although maybe not as fervently 
as cholesterol. Moreover, Vainio et al. also showed that exchanging of ~70% of cholesterol by 
desmosterol in mammalian cell membranes impaired raft-dependent signaling via the insulin 
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receptor, whereas protein secretion, a process highly dependent on membrane composition 
and properties (Gondre-Lewis et al., 2006), was not affected by cholesterol substitution with 
desmosterol. These findings suggest that cholesterol replacement in DRMs may influence 
certain raft-dependent functions while others remain unaffected. Thus, we found no 
significant differences in APP processing, Aβ generation and proteolytic activity of secretases 
between adult DHCR24-/- and aged-matched wt mice, confirming the functional activity of 
desmosterol containing membranes in adult DHCR24-/- brains. Convincingly, the observed 
changes in protein phosphorylation of PKB/Akt and p38 and the membrane association of 
RhoA in young DHCR24-/- mice were annulled in adult knock-out mice, suggesting that either 
cholesterol deficit in early postnatal development has other effects than it has in an adult 
organism, or that desmosterol is indeed capable of efficiently taking over cholesterols’ 
function concerning these pathways. 
 
Cell membranes need to contain sterols that condense lipids, form lipid domains as rafts 
(Simons and Ikonen, 1997), and provide the basis for a proper organization and function of 
membranes. From the point of view of biophysics, it was stated that cholesterol and 
desmosterol are identical sterols (Huster et al., 2005), and our study provides detailed 
evidence of the effective functional substitution of cholesterol by desmosterol. However, in 
living organisms desmosterol does probably not serve for all functions of cholesterol. For 
example, cholesterol is an essential component of crucial metabolic pathways, e.g above all, 
essentially involved in the synthesis of steroid hormones. The most prominent effect of the 
absenteeism of cholesterol regarding these functions is infertility of the DHCR24-/- mice.  
 
4.5 CONCLUSION AND OUTLOOK 
The aim of this study was the analyses of DRM associated membrane organization in 
DHCR24 depleted mice and to evaluate the possible effects on a membrane-related, functional 
level. DHCR24 depletion resulted in reduced brain cholesterol concentrations, affecting DRM 
formation, composition and function in a cholesterol-dependent manner. Surprisingly, the 
entire replacement of cholesterol by desmosterol revealed an efficient functional substitution 
of cholesterol by its direct precursor. 
The two mouse models used in this study, the DHCR24+/- and DHCR24-/- mice were shown to 
be suitable models for cholesterol depletion in vivo, avoiding the disturbing method of 
pharmacological cholesterol extraction. However, interference in cholesterol biosynthesis on 
the level of cholesterol synthesizing enzymes always involves changes in the level of sterol 
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intermediates. Like DHCR7 deficiency in SLOS leads to reduced cholesterol levels paralleled 
by increased levels of 7-dehydrocholesterol, altered DHCR24 activity results in desmosterol 
accumulation. Therefore, one has to take into account that cholesterol reduction in DHCR24 
depleted mice is not necessarily the sole underlying basis for possible resulting effects. The 
observed alterations could also be the consequence of a combination of basal circumstances. 
We tried to evaluate the effects of as many other implicated factors as possible, to rule out that 
alterations other than cholesterol reduction might be jointly responsible for the observed 
findings in DHCR24 depleted mouse brains. 
 
One other possibly affected mechanism that could contribute to altered APP processing and 
Aβ generation in DHCR24-/- brains is the mechanism of endo- and exocytosis. It is generally 
agreed that non-amyloidogenic processing mainly occurs at the cell surface where α-
secretases are present, whereas amyloidogenic processing involves transit through the 
endocytic organelles where APP encounters β- and γ-secretase (Vetrivel and Thinakaran, 
2006). Previous work has reported that inhibition of endocytosis leads to increased α-secretase 
type ectodomain shedding and thus to decreased β-cleavage and reduced release of Aβ (Carey 
et al., 2005; Ehehalt et al., 2003). Since depletion of cholesterol is also known to decrease the 
rate of endocytosis (Rodal et al., 1999), this is likely to contribute to the observed changes in 
APP processing after cholesterol extraction.  
Endocytosis of various plasma membrane molecules occurs in the absence of functional 
clathrin-coated pits. Most of these molecules are found in lipid rafts, which suggests that at 
least some clathrin-independent endocytosis may be raft specific or raft mediated (Lamaze et 
al., 2001). This process seems to be cholesterol sensitive and dependent on dynamin, a high-
molecular weight GTPase, which forms oligomeric rings around the neck of the forming 
vesicle, and aids in the internalisation by severing it from the plasma membrane (Mousavi et 
al., 2004). In ongoing experiments we already started to analyze whether DHCR24 and 
consequent cholesterol depletion affect endocytic activity in brains and primary neurons of 
DHCR24-/- mice. In addition, we want to evaluate the influence of total cholesterol deficiency 
on intracellular trafficking of APP and thus on APP ectodomain shedding.  
First experiments determining endocytic activity of primary neurons and the membrane 
distribution of dynamin suggest that endocytic activity and APP internalization is decreased in 
DHCR24 knock-out neurons. However, further experiments are necessary to confirm these 
date and work out the involved mechanism. In a next set of experiments we want to 
determine, which specific endocytic pathway is affected by DHCH24 deficiency. Therefore, 
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one could infect primary neurons of DHCR24 knock-out and wildtype mice with a variant of 
the SV40, infecting murine cells. SV40 enters the cell specifically via raft-mediated 
endocytosis. Control experiments like Transferrin uptake, which is known to be clathrin 
mediated will reveal possible differences between the two genotypes regarding endocytic 
activity of these primary neurons. Furthermore, one could follow APP internalization in vitro 
using living cell microscopy.  
 
One very surprising result was the finding that melin staining applying histological techniques 
did not reveal any obvious difference between wt and DHCR24 knock-out mice. Since up to 
70% of the brain cholesterol was estimated to be associated with myelin and myelin consists 
to more that 70% of lipids when related to its dry weight, the question arises how the structure 
of myelin is maintained in cholesterol-free knock-out brains. GC/MS analysis and 
determination of myelin protein composition would be an interesting first investigation and 
examining the structure of myelin from DHCR24-/- brains by electronmicroscopic means 
would be a challenging topic to focus on in future experiments. 
 
 
 
 
 
 
 
 
Data presented in this document have partially been published in The EMBO Journal, January 
2006 (see attachment at the end of the document). Two other manuscripts were submitted in 
July and October 2006. 
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5. MATERIAL 
 
 
5.1 PRODUCTS 
  
Product Provider 
  
  
10-20% Tricine Gels Invitrogen 
Acetone Merck 
Agarose Invitrogen 
B27 Invitrogen 
BSA Sigma 
Chemicals Merck or Sigma 
Chloroform Sigma 
Complete Protease Inhibitor Roche    
DEPC Sigma 
DMEM / F12 Invitrogen 
DMSO Sigma 
DNA ladder 100 bp, 2 log Invitrogen 
dNTP mix 10mM Sigma 
DTT Sigma 
ECL Amersham 
Ethanol Merck 
Ethidiumbromide Sigma 
FCS Invitrogen 
Glycerol Sigma 
HPLC grade H2O Aldrich 
Isopropanol Sigma 
L-Glutamine Invitrogen 
MES Sigma 
Methanol Merck 
methyl-β-cyclodextrin Sigma 
Mevilonin Sigma 
Neurobasal medium Invitrogen 
Nitrocellulose membrane 0.45µm BioRad 
Oligonucleotides Microsynth / Sigma 
Paraformaldehyd Sigma 
PCR Buffer II 10x Applied Biosystems 
RNase away Catalys 
SDS Sigma 
Sterols Sigma 
Triton X-100 Sigma 
Trizol Invitrogen 
Tween-20 Sigma 
Xomat LS Films Kodak 
β-mercaptoethanol Sigma 
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5.2 BUFFERS 
  
Buffer Components 
  
DEPC water 500 µl Diethylpyrocarbonate, ddH2O ad 1000 ml 
DNA loading dye 0.25 g Bromophenol blue, 0.25 g Xylene cyanol FF, 
30 g Glycerol, ddH2O ad 10 ml 
EDTA 0.5 M, pH 8.4 186.1 g Na2EDTA x 2H2O, ddH2O ad 1000 ml 
Laemmli Buffer 4x 2.5 ml Tris-HCl 1 M pH 6.8, 4 ml Glycerol, 5 ml SDS 
10%, 50 µl Bromophenol blue 1%, 1 ml β-
mercaptoethanol, ddH2O ad 10 ml 
PBS 10x 90 g NaCl, 2 g KCl, 18 g Na2HPO4 x 2H2O, 2.4 g 
K2HPO4, ddH2O ad 1000 ml 
TBS 10x 24.2 g Tris base, 86.7 g NaCl, ddH2O ad 1000 ml 
TBST 1x 500 µl Tween-20, TBS 1x ad 1000 ml 
Tricine running buffer 10x 121 g Tris base, 179 g Tricine, 10 g SDS, ddH2O ad 
1000 ml 
Tris Glycine transfer buffer 2.9 g Glycine, 5.8 g Tris, 0.37 g SDS, 200 ml 
Methanol, ddH2O ad 1000 ml 
  
 
 
 
 
5.3 INSTRUMENTS 
  
Instrument  Provider 
  
7900 ABI PRISM® Sequence Detection System Applied Biosystems 
Bio Photometer Eppendorf 
Centrifuge: 5417C, 5417R, 5804R Eppendorf 
GeneAmp PCR System 9700 PE Applied Biosystems 
Kodak X-OMAT 2000 Processor Kodak 
Memmert waterbath Fisher 
MP 220 pH meter Mettler Toledo 
Nicon Eclipse TE300 Nikon 
Nikon Eclipse E800 Nikon 
NUAIRE Autoflow CO2 Incubator Inotech 
SKAN VSE-2000-120 sterile hood Skan 
Sorvall RC 26 Plus Kendro 
Spectra Max Fluorescence Reader Bucher 
Thermomixer Eppendorf 
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5.4 KITS 
  
Kit Provider 
  
Amplex Red Molecular Probes/Invitrogen 
DC Protein Assay BioRad 
DNeasy Kit QIAGEN 
ECL Advance Kit Amersham Biosciences 
Full Velocity SYBR Green QPCR Master Mix  Stratagene 
RNase-Free DNase Kit QIAGEN 
RNeasy Kit QIAGEN 
Secretase assays R&D Systems 
SuperSignal West femto Pierce 
Transcriptor First Strand cDNA Synthesis Kit Roche Diagnostics 
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ABBREVATIONS 
  
-/- knock-out 
+/- heterozygous 
+/+  Wildtype 
aaa Gene encoding protein Aaa 
AAA/Aaa Protein A 
ABCA1 ATP-Binding Cassette Transporter A1 
ACAT Acyl-coenzyme A: cholesterol acyltransferase 
AD Alzheimer’s disease 
AICD APP intracellular domain 
ApoE Apolipoprotein E 
APP Amyloid precursor protein 
ATP Adenosine triphosphate 
Aβ Amyloid β-peptide 
BACE β-site APP cleaving enzyme 
BSA Bovine Serum Albumin 
cDNA Complementary deoxyribonucleic acid 
CE Cholesteryl ester 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CTF C-terminal fragment 
ddH2O Double distilled water 
DEPC Diethyl pyrocarbonate 
DHCR24 3β-hydroxysterol-∆24 reductase 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide 
DRM Detergent resistant membrane domain 
DTT Dithiothreitol 
ECL Enhanced chemiluminescence 
EDTA Ethylendiamintetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
EOFAD Early onset familial Alzheimer’s disease 
ER Endoplasmatic reticulum  
FAD Familial form of Alzheimer’s disease 
FAS Fatty acid synthase 
FCS Fetal calf serum 
GAPDH Glyceraldehydes-3-phosphate dehydrogenase 
GPI Glycosyl-phosphatidylinositol  
HDL High density lipoprotein 
HMGCR Hydroxy-3-methylglutaryl coenzyme A reductase 
HMGCS Hydroxy-3-methylglutaryl coenzyme A synthase 
HRP Horse radish peroxidase 
kDa Kilo dalton 
LDL Low density lipoprotein 
LOAD Late onset Alzheimer’s disease 
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mRNA Messenger ribonucleic acid 
NFT Neurofibrillary tangles 
P/S Penicillin / Streptomycin 
PBGD porphobilinogen deaminase 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PGK Phosphoglycerate kinase 
PS Presenilin 
QPCR Quantitative PCR 
RNA Ribonucleic acid 
RT Room temperature or reverse transcription 
sAPP Secreted APP ectodomain 
SD Standard deviation 
SDS Sodium dodecyl sulfate  
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoreses 
SEM Standard error of the mean 
SH-SY5Y Human neuroblastoma cells 
SLOS Smith-Lemli-Opitz syndrome 
SPM Sphingomyelin 
SREBP Sterol-responsive element binding protein 
TBS Tris buffered saline 
TBST Tris buffered saline + Tween 20 
wt Wildtype 
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The role of seladin-1/DHCR24 in cholesterol
biosynthesis, APP processing and Ab generation
in vivo
Arames Crameri1,5, Elisa Biondi2,5, Katrin
Kuehnle1,5, Dieter Lu¨tjohann3, Karin M
Thelen3, Simona Perga2, Carlos G Dotti2,4,
Roger M Nitsch1, Maria Dolores
Ledesma2,4,* and M Hasan Mohajeri1,*
1Division of Psychiatry Research, University of Zurich, Zurich,
Switzerland, 2Cavalieri Ottolenghi Scientific Institute, Universita` degli
Studi di Torino, Orbassano, Italy, 3Department of Clinical Pharmacology,
University of Bonn, Germany and 4Center for Human Genetics, Catholic
University of Leuven and Flanders Interuniversitary Institute for
Biotechnology (VIB4), Leuven, Belgium
The cholesterol-synthesizing enzyme seladin-1, encoded
by the Dhcr24 gene, is a flavin adenine dinucleotide-
dependent oxidoreductase and regulates responses to
oncogenic and oxidative stimuli. It has a role in neuro-
protection and is downregulated in affected neurons in
Alzheimer’s disease (AD). Here we show that seladin-1-
deficient mouse brains had reduced levels of cholesterol
and disorganized cholesterol-rich detergent-resistant
membrane domains (DRMs). This was associated with
inefficient plasminogen binding and plasmin activation,
the displacement of b-secretase (BACE) from DRMs to
APP-containing membrane fractions, increased b-cleavage
of APP and high levels of Ab peptides. In contrast, over-
expression of seladin-1 increased both cholesterol and
the recruitment of DRM components into DRM fractions,
induced plasmin activation and reduced both BACE pro-
cessing of APP and Ab formation. These results establish
a role of seladin-1 in the formation of DRMs and suggest
that seladin-1-dependent cholesterol synthesis is involved
in lowering Ab levels. Pharmacological enhancement of
seladin-1 activity may be a novel Ab-lowering approach
for the treatment of AD.
The EMBO Journal advance online publication, 12 January 2006;
doi:10.1038/sj.emboj.7600938
Subject Categories: neuroscience; molecular biology
of disease
Keywords: Ab; Alzheimer; cholesterol; neurodegeneration;
therapy
Introduction
Accumulation of amyloid-b peptides (Ab) in the CNS is an
invariant feature of the pathology of Alzheimer’s disease
(AD), the most common form of dementia. Ab peptides are
derived from proteolytic cleavage of the amyloid precursor
protein (APP), with the b-secretase (BACE) cleaving at the
N-terminus and g-secretase at the C-terminus of Ab peptides.
Genetic studies of familial AD cases have led to the identifi-
cation of alterations in genes associated with the disease that
result in increased production of Ab peptide or to C-terminal
extended forms that aggregate more readily (Capell et al,
1998; Hardy and Selkoe, 2002). These observations, together
with studies on Ab toxicity (Small et al, 2001), support the
view of a key role of Ab in AD pathophysiology (Huang et al,
1999; Chen et al, 2000; Janus et al, 2000; Morgan et al, 2000;
Mucke et al, 2000; Small et al, 2001; Casas et al, 2004;
Schmitz et al, 2004). Thus, concentrated effort has been
focused on the identification of modifying factors (Corder
et al, 1993) and regulatory mechanisms of the proteases that
control APP cleavage and are involved in Ab production, as
well as on proteases with the capacity to degrade the peptide
(Selkoe, 2001).
Seladin-1, encoded by a single gene (Dhcr24) on chromo-
some 1, is an evolutionarily conserved gene with homologies
to a family of flavin adenine dinucleotide-dependent oxido-
reductases (Greeve et al, 2000). It catalyzes the reduction of
the D24 double bond of sterol intermediates of cholesterol
metabolic pathway (Waterham et al, 2001). As an exemplar,
seladin-1 reduces the D24 double bond of desmosterol, the
immediate precursor of cholesterol, to form cholesterol
(Waterham et al, 2001). Functional deficiency in the Dhcr24
gene causes, in humans, desmosterolosis, a severe autosomal
recessive disorder characterized by gross developmental ab-
normalities and elevated desmosterol levels in plasma
(Waterham et al, 2001). Moreover, seladin-1 is a key regulator
of Ras-induced senescence, and cellular responses to onco-
genic and oxidative stimuli (Wu et al, 2004). Greeve et al
(2000) have previously shown the protective activity of
seladin-1 against oxidative and Ab-mediated toxicity and
that seladin-1 levels are lower in affected neurons of AD
brain.
The cholesterol synthesizing activity of seladin-1 suggests
a possible role in the formation of the cholesterol-rich deter-
gent-resistant membrane domains (DRMs or rafts), but this
activity has not been studied to date. DRMs are operationally
defined as membrane domains resistant to solubilization by
nonionic detergent at 41C (Ciana et al, 2005). The in vivo
counterpart of the DRMs is under intense investigation.
Experimental evidence has revealed the disorganization of
DRMs in AD brains, possibly because of low cholesterol
content (Ledesma et al, 2003a). In a recent study, it has
been described that DRMs participate in the segregation of
APP from BACE, therefore reducing APP b-cleavage and AbReceived: 20 July 2005; accepted: 6 December 2005
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production in cultured primary neurons and CHO cells,
respectively (Abad-Rodriguez et al, 2004). Furthermore, dis-
ruption of DRMs results in diminished activity of the Ab-
degrading enzyme plasmin, because of decreased membrane
plasminogen binding to the plasma membrane (Ledesma
et al, 2000, 2003a, b). Altogether, these data support a possi-
ble link between AD and brain cholesterol loss. In contrast,
the use of statins to reduce cholesterol led to the reduction of
Ab production, favoring the view of high cholesterol as a risk
factor for AD (Simons et al, 1998; Fassbender et al, 2001).
To determine the role of seladin-1 in APP processing and
Ab production, we analyzed seladin-1-deficient mice and we
overexpressed seladin-1 in cultured human neuroblastoma
cells. We provide here evidence for a key role of seladin-1 in
the regulation of brain cholesterol levels, DRM formation,
plasmin activation, APP processing and Ab levels in vivo and
in vitro.
Results
Seladin-1 influences the membrane and cellular
cholesterol levels in mouse brains and in cultured
human neuroblastoma cells
To determine to which extent the levels of brain cholesterol
depend on seladin-1, we first analyzed the effects of genetic
seladin-1 depletion on steady-state cholesterol levels in vivo.
The analysis of seladin-1 mRNA levels in the brain of
wild-type mice, heterozygous mice with depletion of one
(heterozygous) or knockout mice with depletion of both
(homozygous) seladin-1 alleles (Wechsler et al, 2003) re-
vealed a gene-dose-dependent reduction in the heterozygous
mice compared to their wild-type littermates (43.873.3%,
P¼ 0.009). There was no seladin-1 mRNA expression detectable
in the homozygous mice (Figure 1A). The brains of seladin-1
heterozygous mice exhibited an average reduction of 29%
in membrane (P¼ 0.02; Figure 1B) and 15% in total cellular
cholesterol (P¼ 0.042; Figure 1C) compared to wild-type
brains. Furthermore, cholesterol amount was undetectable
in the homozygous mouse brains (Figure 1B and C). To
characterize the effect of seladin-1 expression on cholesterol
metabolism, we analyzed the effects of seladin-1 depletion on
the levels of the cholesterol precursor, desmosterol, and of
the major degradation product of cholesterol in the brain,
24OH-cholesterol. Desmosterol was 5.7-fold (P¼ 0.012) and
50-fold (P¼ 0.00006) increased in heterozygous and homo-
zygous mouse brains, respectively (Figure 1D), indicating
that desmosterol accumulates upon seladin-1 deficiency.
Moreover, decreased seladin-1 expression led to a significant
reduction in the catabolic product 24OH-cholesterol in
heterozygous (24.674.3%, P¼ 0.017) and knockout
(97.670.47%, P¼ 0.0004) compared to control brains.
Altogether, these results unveil for the first time the key
role of seladin-1 in the regulation of brain cholesterol meta-
bolism. Consistent with an essential role of cholesterol in
vertebrate cell viability, homozygous mice did not survive
beyond the first month.
Having demonstrated the consequences of seladin-1
deficiency in cholesterol metabolism, we next tested
whether increasing seladin-1 levels would cause the opposite
effects. To this aim, we generated human neuroblastoma
SH-SY5Y cells constitutively expressing seladin-1. Analysis
of seladin-1 mRNA revealed a significant increase (6847
121%, P¼ 0.0001) in the seladin-1-overexpressing cells
(Figure 1E). Significant increases of 1.9-fold in membrane
cholesterol (P¼ 0.003; Figure 1F) and 1.7-fold in total cellular
cholesterol (P¼ 0.001; Figure 1G) were found in seladin-1-
overexpressing cells when compared to the control cultures,
confirming the bioactivity of the transgene. Consistent with
the in vivo data, desmosterol levels were dramatically
reduced in cells overexpressing seladin-1 (4375.2%,
P¼ 0.001) (Figure 1H), whereas 24OH-cholesterol amounts
were increased (17272.3%, P¼ 0.00001) when compared
to control cultures.
Seladin-1 contributes to the specific recruitment of DRM
proteins and lipids into DRMs
Given the above results and that cholesterol is a main
component of DRMs and affects DRM functions (Simons
et al, 1998; Simons and Toomre, 2000), we first tested
whether changes in seladin-1 expression alter these mem-
brane domains in vivo. Therefore, DRM protein and lipid
composition was analyzed in the brains of wild-type and
seladin-1 heterozygous mice that, in contrast to the seladin-1
homozygous mice, develop normally and survive to adult-
hood without major health problems but present a moderate,
still significant, reduction of cholesterol (see above). DRMs
were isolated upon cold-detergent extraction of total brain
extracts and gradient centrifugation. In the seladin-1 hetero-
zygous brains, significantly lower protein levels were found
in the light fractions 4–6 of the gradient, which correspond to
detergent-resistant membranes (Figure 2A). To determine
whether this reduction of protein content was the conse-
quence of general or DRM-specific protein loss, the flotation
profiles of the DRM markers flotillin 1 and the cellular prion
protein (PrPc) as well as of the non-DRM marker transferrin
receptor (TfR) were analyzed. In agreement with a DRM-
specific shortage, reduction of brain seladin-1 levels resulted
in the displacement of DRM markers, flotillin 1 (Figure 2B
and C) and PrPc (Figure 2D and E), away from the DRM
fractions. Thus, while in wild-type mice 20.271.45% of total
protein, 12.371.21% of total flotillin 1 and 40.574.68% of
total PrPc were present in DRM fractions 4–6, these percen-
tages decreased to 13.871.56, 5.172.19 and 12.575.32%,
respectively, in seladin-1 heterozygous mouse brains. All the
differences found were statistically significant (Po0.03). In
contrast, no change was observed in the flotation profile of
the non-DRM protein TfR (Figure 2F and G).
Conversely, significantly higher protein levels were found
in the light fractions 4–6 of the seladin-1-overexpressing
cell extracts compared to control cells (31.672.02 and
22.272.02%, respectively, P¼ 0.01; Figure 2H). Consistent
with a recruitment of DRM-specific proteins and not to a
general protein contribution, flotillin 1 (Figure 2I and J) and
PrPc (Figure 2K and L) were enriched in fractions 4–6
of seladin-1-overexpressing cell gradients when compared
to control cells, whereas TfR remained always in detergent-
soluble heavy fractions (8–10) (Figure 2M and N).
Quantitative analysis showed that, 4.871.15% of total flotil-
lin 1 and 10.471.73% of total PrPc float to DRMs in control
cells, which increased to 18.772.66 and 30.572.89%,
respectively, in seladin-1-overexpressing cells (P¼ 0.004
and 0.001).
The analysis of the distribution of several lipids in the
flotation gradient fractions revealed that the presence of
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cholesterol, sphingomyelin and the ganglioside GM1 was
also modulated by seladin-1 levels, whereas no changes in
the amounts of desmosterol and total phospholipids were
detected in the DRM fractions in vivo and in vitro
(Supplementary Figures 1 and 2).
Altogether, these results indicate that seladin-1 is required
for the specific recruitment of DRM proteins and lipids into
detergent-insoluble membrane domains and that its defi-
ciency results in DRM disorganization, evident by displace-
ment of DRM-specific lipids and proteins.
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Figure 1 The level of cholesterol is dependent on seladin-1 expression in vivo and in vitro. Seladin-1 mRNA expression level was 44% lower in
heterozygous (þ /) compared to wild-type mouse brains (þ /þ ), whereas no seladin-1 mRNA was detectable in the brains of seladin-1
knockout mice (/) (A). In brain extracts of seladin-1 heterozygous (þ /) mice, membrane cholesterol (B) and cellular cholesterol (C) were
significantly reduced by 29 and 15%, respectively, compared to wild-type (þ /þ ) littermates. In knockout (/) mice, membrane and cellular
cholesterol were undetectable (B, C). Desmosterol was 5.7- and 50-fold increased in heterozygous (þ /) and in knockout (/) brains,
respectively, when compared to wild-type littermates (D). In seladin-1-overexpressing SH-SY5Y human neuroblastoma cells, seladin-1 mRNA
expression level was 680% higher compared to control cells (E), and membrane cholesterol (F) and cellular cholesterol (G) were significantly
increased by 1.9- and 1.7-fold, respectively. Desmosterol was significantly lower (two-fold) in seladin-1-overexpressing cells compared to
control cultures (H). Values in panels A–D and E–H are expressed as a percentage change in the corresponding values of wild-type mouse
brains or control cells, respectively, that were considered as 100%. The graphs show the average and standard error from three different mouse
brains for each condition, and from three independent seladin-1-overexpressing and control SH-SY5Y cultures. Statistical significance is
indicated by asterisks: *Po0.05, **Po0.009, ***Po0.0002.
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Seladin-1 affects DRM-dependent plasminogen binding
and activation
Given the influence of seladin-1 on DRM composition, we
reasoned that changes in its expression would also affect
DRM-dependent functions. Plasminogen binding to the
membrane leads to the activation of the Ab-degrading en-
zyme plasmin in DRMs (Ledesma et al, 2003a). Therefore, we
first investigated whether changes in seladin-1 expression
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affect plasminogen binding and plasmin activity in vivo.
Endogenous plasmin activity was reduced in heterozygous
brains when compared to controls (Figure 3A). To analyze
plasminogen binding, exogenous plasminogen was added to
isolated membranes and plasmin activity was measured.
Seladin-1 deficiency resulted in reduced plasmin activity,
indicating a diminished ability of heterozygous seladin-1
brain membranes to bind plasminogen (Figure 3B).
Accordingly, the amount of endogenous plasminogen bound
to the membrane was clearly reduced in seladin-1 hetero-
zygous mouse brains (42.9710.9% of that in wild-type
brains, P¼ 0.005; Figure 3C and E), whereas the endogenous
levels of total plasminogen were similar in all mouse brains
(Figure 3D and F). Endogenous plasmin activity was also
measured in membranes derived from control and seladin-1-
overexpressing cells. The latter exhibited a clear increase in
plasmin activity (Figure 3G). Furthermore, plasmin activity
upon addition of exogenous plasminogen was also higher in
seladin-1-overexpressing cells than in control cells, indicating
an increased ability of seladin-1-overexpressing cell-derived
membranes to bind plasminogen (Figure 3H). This was
further confirmed by Western blot analysis showing that
while there were no significant differences on the endogen-
ous levels of total plasminogen in control and seladin-1-
overexpressing cells (Figure 3J and L), the amount of
plasminogen bound to the membrane was clearly increased
in the latter (247714.7%, P¼ 0.004; Figure 3I and K).
Seladin-1 alters BACE1–APP membrane
compartmentalization, APP b-cleavage and Ab
generation in vitro and in vivo
DRMs segregate a major pool of the APP-b-secretase BACE1
from its non-DRM substrate APP, restricting APP b-cleavage
and Ab production in cultured primary neurons and CHO
cells, respectively (Abad-Rodriguez et al, 2004). Hence, we
determined whether low levels of seladin-1, leading to
decreased cholesterol concentrations and DRM alterations,
affect BACE1–APP membrane segregation and their functional
interaction in vivo. The flotation profiles revealed that BACE1
was displaced from light fractions 4–6 to APP-containing
heavy fractions in seladin-1 heterozygous mouse brains
compared to wild-type brains. The percentages of total
BACE1 in DRM fractions 4–6 in wild-type and heterozygous
seladin-1 mice were 36.473.58 and 9.771.97%, respectively
(P¼ 0.003; Figure 4A and B). In contrast, no changes in the
flotation profile of APP, as well as in its concentration, were
detected between the genotypes (Figure 4C and D). To test
if the changes in membrane compartmentalization had a
functional consequence, we measured the levels of APP
b-cleavage. The amount of the APP b-C-terminal fragment
(b-CTF) was significantly increased (201716%, P¼ 0.04) in
seladin-1 heterozygous mouse brains (Figure 4E and F and
Supplementary Figure 4A).
To assess whether high levels of seladin-1 would reverse the
effects observed upon its deficiency, the flotation profiles of
BACE1 and APP were also analyzed in seladin-1-overexpressing
and control cells. While APP always remained in the heavy
fractions 9–10 (Figure 4I and J), more BACE1 was recruited in
the light fractions upon seladin-1 overexpression (Figure 4G
and H). Quantitative analysis revealed that 54.479.8% of
BACE1 is in the APP-containing fractions 9–10 in the control
cells, whereas the percentage significantly diminishes to
35.674.3% in seladin-1-overexpressing cells (P¼ 0.04; Figure
4H and J). Consistent with the enhanced membrane segregation
of BACE1 from APP, the generation of APP b-CTF was signifi-
cantly reduced (34711%, P¼ 0.04) in seladin-1-overexpressing
cells (Figure 4K and L). Taken together, the above observations
reveal an important role of seladin-1 in the regulation of
BACE1–APP interaction and thus in APP b-cleavage.
Finally, we determined whether these alterations affect the
levels of Ab, utilizing ELISA systems that measure specifically
murine and human Ab peptides. In concert with higher
amyloidogenic APP processing, Ab40 was significantly in-
creased (152716%, P¼ 0.027; Figure 5A) in total brain
extracts of heterozygous mice. Because the endogenous
mouse Ab42 levels are extremely low in young wild-type
mice, as previously reported (Refolo et al, 2001), the Ab42
measurements were below the detection level. We therefore
analyzed age-matched wild-type and seladin-1 heterozygous
mice cross bred to the Tg2576 SwAPP mouse line (SwAPP/
seladin-1). The SwAPP mice overexpress human APP carry-
ing the Swedish mutations under the regulatory sequence
of the neuronal Prp promoter. These mutations located at the
N-terminus of the Ab peptide lead to increased b-cleavage and
therefore elevated levels of Ab40 and Ab42 (Hsiao et al, 1995).
In accordance with the murine ELISA data, Ab40 was sig-
nificantly increased in heterozygous SwAPP/seladin-1 mouse
brains (270731%, P¼ 0.024; Figure 5B). In these mice,
Ab42 levels also revealed a significant increase compared to
the SwAPP littermates (15970.3%, P¼ 0.015; Figure 5C),
whereas the ratio of Ab40 to Ab42 did not significantly differ
between the genotype groups (136731%; Figure 5D), sug-
gesting that the changes in Ab levels were not due to a change
in the g-secretase activity. These data demonstrate that the
elevation of Ab concentrations in the seladin-1-deficient mice
is caused by enhanced b-cleavage of APP in vivo.
Figure 2 Seladin-1 modulates DRM protein composition. Homogenates from wild-type (þ /þ ) and seladin-1 heterozygous (þ /) mouse
brains and from control and seladin-1-overexpressing SH-SY5Y cells were extracted and centrifuged in a sucrose gradient. Fractions were
collected and numbered from the lightest to the heaviest (2 to 10). The amount of protein in each gradient fraction is expressed as a percentage
of the total protein along the gradient (A, H). Representative Western blots of the gradient fractions using antibodies against the DRM marker
proteins flotillin 1 (B, I) and PrPc (D, K), and the non-DRM protein TfR (F, M) are shown. Graphs on the right show the distribution of flotillin 1
(C, J), PrPc (E, L) and TfR (G, N) in each fraction as a percentage of the total amount of the respective proteins along the entire gradient.
Seladin-1 deficiency in mouse brains led to a significant decrease of the protein amount in fractions 4–6 corresponding to DRMs (A) and
resulted in significantly lower amounts of DRM markers in these fractions (B–E), whereas the distribution of TfR did not differ between wild-
type (þ /þ ) and heterozygous (þ /) mouse brains (F, G). In contrast, overexpression of seladin-1 in SH-SY5Y cells led to an increased
amount of protein in fractions 4–6 compared to control cells (H) and to significantly higher levels of the DRM markers flotillin 1 (I, J) and PrPc
(K, L), whereas the distribution of the non-DRM protein TfR remained unchanged (M, N). The graphs show the average and standard error
from three different mouse brains for each condition and from three independent seladin-1-overexpressing and control SH-SY5Y cultures.
Asterisks show statistical significance of the difference in the total amount of respective proteins in the DRM fractions 4–6. *Po0.02,
**Po0.008.
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Figure 3 Plasminogen binding and plasmin activation depend on seladin-1 levels. Plasmin activity (expressed in arbitrary units) was
measured at the indicated times in membranes isolated from wild-type (þ /þ ) and seladin-1 heterozygous (þ /) mouse brains. The ability to
bind plasminogen was monitored by measuring plasmin activity after the addition of exogenous plasminogen to the membrane fractions. Both
endogenous plasmin activity (A) and the ability to bind plasminogen (B) were clearly reduced in the heterozygous mouse brains. Membrane-
bound plasminogen was significantly decreased in heterozygous (þ /) brains (C, E). Endogenous levels of cellular plasminogen, however,
were not altered in wild-type (þ /þ ) and heterozygous mouse brains (D, F). The amount of tubulin is shown as a loading control in all
Western blots (C, D, I, J). In contrast, seladin-1 overexpression in vitro resulted in increased endogenous plasmin activity (G). Moreover, when
exogenous plasminogen was added to isolated membranes, plasmin activity was higher in membrane fractions isolated from seladin-1-
overexpressing cells (H). Membrane-bound plasminogen was significantly elevated in these cells (I, K). Cellular plasminogen levels did not
differ between overexpressing and control cells (J, L). Data in all the graphs correspond to mean value and standard error from three different
mouse brains for each condition and from three independent seladin-1-overexpressing and control SH-SY5Y cultures. **Po0.006.
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In contrast, the generation of both Ab40 and Ab42 was
reduced to 78.574.8 and 71.4876.7% (P¼ 0.001 and 0.003,
respectively; Figure 5E and F) in seladin-1-overexpressing
compared to control cells, whereas the ratio of Ab40 to Ab42
revealed no significant difference (Figure 5G). LDH and MTT
assays confirmed that there was no interference with the
viability of cells in both cultures, ruling out the potential
effect of the transgene expression on cell survival. In the LDH
and MTT assays, 10273.2 and 9871.8% viable cells were
found in seladin-1-overexpressing cultures, respectively,
when the corresponding levels of control cells were set as
100%. Altogether, these data confirm the crucial role of
seladin-1 protein and cholesterol levels in modulating Ab
generation.
Discussion
The results of this study show that cholesterol levels are
modulated by modifying the expression of the cholesterol-
synthesizing enzyme, seladin-1. Our approach is different
from previous work that relied on pharmacological inhibition
of early steps of cholesterol synthesis or on using lipid-
extracting drugs in cultured cells and in vivo that has led to
controversial results (Simons et al, 1998; Sparks et al, 2000,
2002; Fassbender et al, 2001; Kirsch et al, 2003; Park et al,
2003; Abad-Rodriguez et al, 2004). We show that seladin-1
deficiency results in lower membrane cholesterol levels in
mouse brains and, as a consequence, in altered DRMs. This in
turn contributes to reduced membrane binding of plasmino-
gen and plasmin activation and to increased APP b-cleavage
and Ab production in vivo. Importantly, the overexpression
of seladin-1 caused the opposite biochemical changes as
observed for seladin-1 deficiency.
In our colony, seladin-1 homozygous mice were born to
published frequency (Wechsler et al, 2003). These mice,
however, were extremely weak, half of the size of littermates
and most of them (90%) died before reaching the age of 3
weeks (Supplementary Figure 4). Therefore, to study the
effects of a moderate cholesterol reduction, we analyzed the
seladin-1 heterozygous mice that develop normally and have
no problem of health, fertility or longevity. Neuropathological
and immunohistochemical examinations of these mice re-
vealed no detectable differences between wild-type and het-
erozygous mice concerning morphology, cellular distribution
and viability of the brain cells (unpublished data).
Considering that cholesterol is an essential component of
vertebrate cell membranes and exhibits essential biological
roles, it is striking that seladin-1 knockout mice survive
beyond birth. The question arises as to which mechanism/s
enable the seladin-1 knockout mice to reach embryonic
maturation and postnatal development, even if short. With
mice, in contrast to humans, cholesterol passes the placenta.
Therefore, one reasonable answer is that circulating choles-
terol, contributed from the heterozygous mother, suffices for
early development. In this scenario, soon after birth seladin-1
knockout mice are compromised due to the deficiency to
synthesize cholesterol. Alternatively, embryonic develop-
ment and the short postnatal survival in the seladin-1 knock-
out mice may depend on the substitution of cholesterol by
desmosterol. In agreement with this possibility, one study
indicated that desmosterol could replace cholesterol without
deleterious effects in fibroblasts (Rothblat et al, 1970).
Although this last scenario would imply a non-essential role
of cholesterol in early developmental processes, it also in-
dicates an essential requirement of cholesterol for full ma-
turation. Indeed, seladin-1 heterozygous mice, which show a
29% reduction of brain membrane cholesterol, exhibit altera-
tions in DRM composition and DRM-dependent functions.
Moreover, although changes in seladin-1 expression also
affect the amount of desmosterol in mouse brains, the
distribution of this lipid in DRMs was not altered. In addition,
experimental increase of desmosterol levels in cultured cells
did not affect DRM-related functions analyzed in this work,
whereas moderate reduction of cholesterol changed these
parameters (Supplementary Figures 2 and 3). These results
strongly support our conclusion that the reduction of choles-
terol but not the increase of desmosterol levels mediates the
seladin-1-induced alterations in DRMs observed in vivo.
Altogether, our data reveal that proper brain maturation
requires the maintenance of a certain steady-state level of
brain cholesterol and that a modest reduction of cholesterol
in brain could have deleterious consequences.
Seladin-1 can exert antiapoptotic function, and apoptosis
may lead to elevated Ab levels in the brains of AD patients
and mouse models (Gervais et al, 1999; Mohajeri et al, 2002).
We found, however, no apoptotic cell death in the hetero-
zygous and wild-type mouse brains. Moreover, the viability
of seladin-1-overexpressing and control cultures did not differ
at any time points. Taken together, these data provide the
evidence that the effects described in this work are not a
consequence of the antiapoptotic function of seladin-1.
The finding that low expression of seladin-1 paralleled a
reduction in brain membrane cholesterol offers a new per-
spective on the role that this protein might play in AD
pathology. Because seladin-1 is downregulated in vulnerable
areas of brains in AD patients (Greeve et al, 2000), it is
reasonable to think that low levels of seladin-1, promoted by
yet to be identified causes, are responsible for the membrane
cholesterol reduction found in such brains (Ledesma et al,
2003a). This would consequently lead to Ab accumulation
via a combination of inefficient Ab degradation (due to low
plasmin activity) and increased APP amyloidogenic cleavage.
Iivonen et al (2002), in contrast, could not find an association
between reduced seladin-1 transcription levels in AD brains
and Ab content. The fact that cholesterol levels were not
measured in this study together with the low number of
samples analyzed precludes drawing a definitive conclusion.
Indeed, cholesterol loss has been observed in a significant
number but not in all AD brains (Ledesma et al, 2003a).
Altogether, these data suggest that compensatory mechan-
isms to the effects of seladin-1 deficiency on cholesterol levels
might exist that would differ among AD patients. Moreover,
alternative mechanisms (i.e. mutations in APP or presenilins)
would be responsible for Ab accumulation in certain AD
cases. Further research, including large-scale studies, is
required to clarify these matters.
Seladin-1 also participates in the Ras/p53 pathway by
binding to p53 leading to p53 accumulation (Wu et al,
2004). Although the domain of seladin-1 involved in choles-
terol synthesis is apparently not required for binding to p53,
Ras signaling is modulated in a cholesterol- and DRM-depen-
dent manner (Prior et al, 2003; Parton and Hancock, 2004).
These examples suggest that altered seladin-1 levels could
contribute to disease conditions through both cholesterol-
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dependent and -independent modulation of cell survival/
death pathways.
In conclusion, our data provide the evidence for a role of
seladin-1 in providing enough cholesterol to generate and
maintain proper DRM composition and function (Simons and
Toomre, 2000). In this regard, the alterations produced by
seladin-1 deficiency, such as increased APP amyloidogenic
cleavage, Ab peptide accumulation and decreased plasmin
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levels, could explain both amyloid build-up and cytopathol-
ogy in AD in vivo. Our study demonstrates the consequences
of cholesterol loss in brain cells in vivo and provides ground-
work to better understanding of the roles of cholesterol in
health and disease.
Materials and methods
Cell culture
The open reading frame of human seladin-1 (KIAA0018;DHCR24)
(Swiss-Prot: Q15392) was cloned in pcDNA3 expression plasmid
(Invitrogen). A hemagglutinin tag was added in-frame to the
C-terminus of the protein. The expression was controlled by the CMV
promoter. SH-SY5Y cells were cultured in DMEM NUT-F12 medium
(Invitrogen) containing 10% fetal calf serum (FCS), 5% horse
serum (HS) and 5000 U/ml penicillin and 5000mg/ml streptomycin.
Transfections were performed using Lipofectamine 2000 (Invitro-
gen). Stably transfected cultures were established by addition of
125 mM G418 (Invitrogen) to the medium. SH-SY5Y cells stably
expressing the EGFP protein under the control of the same promoter
were used as controls.
Cell viability assays
Before harvesting the cells for quantification of Ab levels, the
viability of the seladin-1-overexpressing and SH-SY5Y control
cultures was determined using the MTT (Sigma) and the LDH
assay (Sigma) according to the manufacturers’ instructions.
Mice
Heterozygous breeding pairs with target depletion of one seladin-1
allele were received from Dr E Feinstein (Quark Biotech Inc.).
Seladin-1-deficient mice were bred and genotyped as previously
described (Wechsler et al, 2003). In addition, seladin-1 hetero-
zygous mice were bred to SwAPP transgenic mice overexpressing
human APP harboring the Swedish double mutation (Hsiao et al,
1995) (SwAPP/seladin-1). All animal experiments and husbandry
were performed compliant with national guidelines. All mice were
analyzed at 3 weeks of age.
Antibodies, Western blots and quantification
Monoclonal anti-flotillin 1 (clone 18; Transduction Laboratories),
monoclonal anti-PrPc POM-1 (kindly provided by Dr A Aguzzi,
University of Zurich), monoclonal anti-TfR (clone CD-71; Santa
Cruz Biotechnology Inc.), polyclonal anti-human plasminogen
(Biogenesis), monoclonal anti-N-terminal APP (clone 22C11;
Roche), polyclonal chicken anti-BACE1 (raised against Fc-Asp 2-
fusion protein, kindly provided by Dr C Dingwall, GlaxoSmithK-
line), polyclonal anti-C-terminal APP (Sigma) and monoclonal 6E10
(Signet) antibodies were used for Western blot analysis. Mono-
clonal anti-tubulin (Calbiochem) was used as an internal loading
control and for normalization of densitometric analysis of the
immunoreactive bands. All antibodies were diluted in 5% fat-free
milk in 35 mM Tris–HCl (pH 7.4) and 140 mM NaCl (TBS buffer).
For Western blotting, 15% polyacrylamide–SDS gels and Novex 10–
20% Tricine gels (Invitrogen) were used. Proteins were transferred
to a nitrocellulose membrane (0.45mm pore; Bio-Rad). Species-
specific peroxidase-conjugated secondary antibodies and the ECL
detection method (Amersham) were subsequently used. Quantifica-
tion of immunoreactive bands was carried out by densitometry of
the scanned autoradiograms under conditions of non-saturated
signal using the NIH-image software.
Ab measurement
Hemi-brains from 3-week-old mice with the depletion of one
seladin-1 allele (heterozygous) and wild-type littermates (n¼ 4 for
each) as well as their littermates carrying the SwAPP transgene
were homogenized in a buffer containing 100 mM Tris and 150 mM
NaCl (pH 7.4) and proteinase inhibitors (Roche). These total
extracts were analyzed by a modified sandwich ELISA that detects
specifically either Ab40 or Ab42 (Takeda, Japan) according to the
provider’s protocol. Ab was captured with a specific anti-Ab
antibody (BNT77). Ab species ending in residue 40 or 42 were
measured using horse radish peroxidase (HRP)-coupled monoclonal
antibodies specific for Ab40 (HRP-conjugated BA27) and Ab42 (HRP-
conjugated BC05) sequence. Seladin-1-overexpressing SH-SY5Y and
control cells were cultured in a minimum volume of serum-free
OPTIMEM medium (Invitrogen) for 30 h and homogenized in their
supernatant by 10 passages through a 22-gauge syringe on ice. Ab40
and Ab42 levels were analyzed by ELISA as described above.
Quantitative RT–PCR
Total RNA from cells and brain tissue was extracted using TRIzol
reagent (Invitrogen) following the manufacturer’s instruction.
Primers specific to human seladin-1 transgene, 50-CCGTCCGAAAA
CTCAG-30 and 50-GCGGTGGTAGTAGTGT-30, and to murine seladin-
1, 50-CATCGTCCCACAAGTATG-30 and 50-CTCTACGTCGTCCGTCA-30,
were designed using the program LC probe design software (Roche).
Seladin-1 mRNA was quantified in three independent cell cultures
and mouse brains (n¼ 5 for each group). The housekeeping genes
phosphoglucokinase and porphobilinogen deaminase were used as
reference genes. These two genes were selected based on our
unpublished results showing a constant expression of these genes
in various experimental conditions in vitro and in vivo, respectively.
Light Cycler quantitative real-time PCR was performed with an RNA
SYBR Green kit (Roche Diagnostics).
Total and membrane extract preparation
SH-SY5Y cells or mouse brains were homogenized in phosphate
buffer saline containing 9% sucrose and protease inhibitors (CLAP:
pepstatin, antipain, chymostatin, each at a final concentration of
25 mg/ml) using 10 strokes in a dounce homogenizer and 10
passages through a 22-gauge syringe on ice. The samples were
centrifuged for 10 min at 41C and 700 g and the supernatants
considered as total extracts. A further centrifugation of the
supernatant was performed at 100 000 g for 1 h at 41C to pellet
the membrane fraction. Protein concentration was quantified by the
BCA method (Bio-Rad).
Detergent extraction and DRM isolation
Total SH-SY5Y cell or mouse brain extracts were incubated for 1 h at
41C in 1% Triton X-100, 25 mM MES pH 7.0, 5 mM DTT, 2 mM EDTA
and CLAP. The extracts were mixed with 90% sucrose prepared in
MBS buffer (25 mM MES pH 7.0, 150 mM NaCl and CLAP) to reach
a final concentration of 60% and over-layered in an SW40
centrifugation tube with a step gradient of 35 and 5% sucrose in
MBS. After centrifugation at 100 000 g for 18 h at 41C, 11 fractions
Figure 4 Seladin-1 alters BACE1–APP membrane segregation and APP b-cleavage. APP and BACE1 distribution along the sucrose gradient
fractions of seladin-1 wild-type (þ /þ ) and heterozygous (þ /) mouse brains (A–D) and from control cells and seladin-1-overexpressing SH-
SY5Y (G–J) was analyzed by Western blot using specific antibodies. Left pictures show representative examples. Graphs on the right indicate
the amount of BACE1 (B, H) and APP (D, J) in each fraction as a percentage of total BACE1 and APP, respectively. In seladin-1 heterozygous
(þ /) mouse brains, BACE1 was displaced from fractions 4–6 (DRM fractions) to APP-containing heavy fractions 8–10 (A, B), whereas the
APP flotation profile did not change between the groups and APP remained in the heavy fractions (C, D). In contrast, seladin-1 overexpression
resulted in a significant decrease of BACE1 in the APP-containing fractions (G, H). There was no change in APP distribution in seladin-1-
overexpressing compared to control cells (I, J). APP b-cleavage was analyzed by Western blot of cellular extracts containing an equal amount of
protein prepared from wild-type (þ /þ ) and heterozygous (þ /) mouse brains (E) and from control and seladin-1-overexpressing SH-SY5Y
cells (K). Levels of APP b-CTF (see also Supplementary Figure 4A) were normalized to the amount of full-length APP (F, L). Seladin-1
deficiency revealed a significant two-fold increase in the amount of b-CTF in heterozygous (þ /) mouse brains (F). In concert to the in vivo
data, overexpression of seladin-1 in SH-SY5Y cells led to a significant decrease (34%) of APP b-CTF (L). The ratio of b-CTF to APP in wild-type
(þ /þ ) mouse brain (F) and in control SH-SY5Y cells (L) was considered as 100%. Data in all the graphs correspond to mean value and
standard error from three different mouse brains for each condition and from three independent seladin-1-overexpressing and control SH-SY5Y
cultures. *Po0.05, **Po0.004.
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were collected from the top of each tube. Fractions 4–6 were
identified as the DRM fraction by the presence of the DRM markers
flotillin 1, PrPc and GM1 in the control samples.
Lipid analysis
Lipids were extracted from membrane pellets as described (Bligh
and Dyer, 1959). Cholesterol, sphingomyelin or desmosterol was
subsequently analyzed by thin-layer chromatography (TLC) on
silica gel 60 HPTLC plates using a two-solvent system (hydrophilic
running solvent: chloroform/acetone/acetic acid/methanol/water
(50:20:10:10:5); and hydrophobic solvent: hexane/ethyl acetate
(5:2)). The ganglioside GM1 was analyzed by slot-blot using
cholera toxin subunit B linked to a peroxidase (Sigma). Quantifica-
tion was carried out by densitometry of the scanned TLCs or
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Figure 5 Seladin-1 affects Ab generation in vivo and in vitro. Measurement of murine Ab40 levels in wild-type (þ /þ sel) and seladin-1
heterozygous (þ / sel) mouse brains without overexpression of the APP transgene revealed a significant increase of the murine Ab40 peptide
in the latter (n¼ 4) (A). Ab40 levels of wild-type mouse brains were considered as 100%. *P¼ 0.027. Quantification of Ab40 and Ab42 in the
brains of seladin-1 wild-type and heterozygous mice with the simultaneous overexpression of SwAPP confirmed that seladin-1 deficiency leads
to higher Ab steady-state levels. Brain Ab40 levels showed a significant 2.7-fold increase (*P¼ 0.024) in heterozygous (SwAPP/þ / sel)
mouse brains compared to seladin-1 wild-type littermates expressing solely the SwAPP transgene (SwAPP/þ /þ sel) (B). Levels of soluble
Ab42 were significantly increased by 1.6-fold (*P¼ 0.015) in heterozygous (SwAPP/þ / sel) mouse brains (C). The ratio of Ab40 to Ab42 levels
revealed no significant differences between the two genotypes (D). In seladin-1-overexpressing SH-SY5Y cultures, Ab40 (E) and Ab42 (F) were
significantly decreased when compared to control cultures (n¼ 10 for each, **P¼ 0.001 and 0.003, for Ab40 and Ab42, respectively), whereas
the ratio of Ab40 to Ab42 levels did not show significant differences between the two groups (G).
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autoradiograms under conditions of non-saturated signal using
the NIH-image software. Phospholipids were determined using the
Phospholipid B kit (WAKO) according to the manufactures’
protocol.
Sterol analysis
Confluent cells (80%) were cultured in FCS/HS free DMEM NUT-
F12 medium without phenol red during 24 h, washed once with ice-
cold PBS containing 2 mg/ml BSA (Sigma) and twice with PBS. The
sterols were extracted twice from confluent cells grown in a tissue
culture dish (diameter 10 cm) using 4 ml hexan/isopropanol (3:2)
containing 1mg epicoprostanol as an internal standard. Similarly,
sterols were extracted from fontal brain regions expanding from
interaural regions 6 to 4 and from each fraction of the flotation
gradient. Gas chromatography–mass spectrometry was performed
to determine the total levels of the extracted sterols as described
(Lutjohann et al, 2002).
As an alternative method, we also measured cholesterol in total
and membrane extracts containing equal amounts of protein (40mg)
using the Ecoline 25 cholesterol kit (Merck). The optical density
was measured at 500 nm. Pure cholesterol solutions (Sigma) were
used as standards. The amounts of all sterols are normalized to the
corresponding protein amounts (brains) or the number of cultured
cells.
Desmosterol addition and cholesterol reduction in SH-SY5Y
cells
Desmosterol and methyl-b-cyclodextrin (Sigma) were complexed as
described previously for cholesterol by Klein et al (1995). These
complexes containing 0.3 mM desmosterol were added to the
medium of SH-S5Y5 cells at a final 1:10 dilution together with
2 mg/ml free desmosterol and incubated for 1 h at 371C. In certain
experiments, before the addition of desmosterol complexes, the
cells were incubated for 48 h with 0.4mM mevilonin (Sigma) and
1 mM methyl-b-cyclodextrin to extract 30% cholesterol as described
by Abad-Rodriguez et al (2004). The incorporation of desmosterol
was monitored by TLC using pure desmosterol (Sigma) as standard.
Cholesterol reduction was monitored by the Ecoline 25 kit as
described above. Cell viability after these treatments was not
affected (Estus et al, 1997).
Plasminogen binding and plasmin activity
A 200mg portion of freshly prepared membrane extracts from
SH-SY5Y cells or mouse brains was resuspended in Hank’s balanced
saline solution and 0.1% ovalbumin (Sigma) and was placed in
a 96-multiwell plate in the presence of 2 mM chromogenic peptide
to measure endogenous plasmin activity. In parallel experiments,
plasminogen binding to cellular membranes was determined by
addition of 2 mM human plasminogen to the same extracts. Plasmin
enzymatic activity was assayed using the chromogenic substrate
S-2251 (Chromogenix) specific for this protease. Absorbance was
measured at 371C and 405 nm in an ultramicroplate reader Elx808iu
(BioteK, Instruments Inc.) every 5 min.
Quantification of APP C-terminal fragments
Equal amounts of total extracts (40 mg) from either SH-SY5Y cells or
mouse brains were submitted to 15% PAGE–SDS, transferred to
nitrocellulose and blotted with either 6E10 or the anti-APP
C-terminal antibody to detect full-length APP and its C-terminal
fragments, respectively. Quantification was carried out by densito-
metry of the scanned autoradiograms using the NIH-image soft-
ware. The amount of the C-terminal fragments was normalized to
the amount of full-length APP in each lane.
Statistical analysis
Data were collected by investigators blinded to the experimental
setup and were statistically analyzed by non-parametric Mann–
Whitney U-test. In all graphs, mean7s.e. (standard error of the
mean) are shown. P-values o0.05 were considered to be
statistically significant.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
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